Browse by Topic

(1-001) A Quantitative Study of the Causes of Drug Shortages in Saudi Arabia: A Healthcare Professionals Perspective and Views

(1-021) Impact of Drug Supply Chain Issues on Outpatient Drug Shortages in the Veterans Health Administration, 2017-2020

(1-036) Evaluating and Describing Clinical Pharmacist Feedback and Activity in a Newly Consolidated Comprehensive Chronic Care Clinic

(1-157) A Survey of Pharmacists on Naloxone Prescribing: Where to Next?

(1-158) Analysis of letters of recommendation for predictive factors for admission into a professional pharmacy curriculum

(1-196) Investigating the Influence of Statin Prescription Labeling on the Rate of Statin-Associated Muscle Symptom Adverse Drug Reaction Reports

(1-230) Assessing Impact of Pharmacy Point-of-Sale Operations on Third-Party Revenue at an Indian Health Service Facility.

(1-276) Implementation of a Distribution Pharmacy Controlled Non-Formulary Optimization Process

(1-359) VA Puget Sound Staffing Model: A Time-and-Motion and Workload Study

(1-375) Evaluating the Impact of Enhanced Integration of Clinical Pharmacist Practitioners in Patient Aligned Care Teams

(2-158) Usability of Retail Pharmacy Websites in the United States

(2-162) Analysis of Conflicts-of-Interest in the Comprehensive Management of Angina with Nonobstructive Coronary Arteries (ANOCA) Review

(2-194) Comparing the Cost Effectiveness of Unit-Dose Packaging for Selected Oral Medications Between On-Site Repackaging, Repackaging Third-Party Vendor, and Direct Purchase from Wholesaler

(2-207) Evaluation of Pharmacists’ Perceived Barriers to Administer Long-Acting Injectable Cabotegravir for HIV PrEP.

(2-217) Pharmacist Deeds for Critical Needs: Effects of Pharmacist Intervention on Medication Preservation During Hydrocortisone Shortage

(2-254) Evaluation of an interchange program for intravenous biosimilar products at a community hospital

(2-259) The Evaluation of DKA Insulin Protocol at Broward Health Hospitals

(2-295) ADC Stocking Schedule and Inventory Management Optimization Improves Inpatient Medication Availability

(3-164) Assessment of Discharge Medications Following Therapeutic Interchange of Frequently Exchanged Drug Classes

(3-328) Impact of Formulary Decision and Electronic Medical Record (EMR) Enhancements on Intravenous Acetaminophen Use

(3-337) More Time, Less Waste: The Impact of Mobile Dispense Tracking for Hand-Delivered Medications on Pharmacy Workload at an Academic Medical Center

(4-001) Utilizing a Plan-Do-Study-Act System to Implement USP <800> at a Central-Fill Pharmacy

(4-002) Utilization of a Healthcare Failure Mode and Effect Analysis to Optimize the Management of Narcotic Injectable in Pharmacy

(4-003) Implementation of a CPOE Dispensation Dashboard & ADC Focused Dispensation Model to Achieve Operational Efficiency at a Community Hospital

(5-030) Assessing Indomethacin Suppository Cost Versus Savings for Hospital Pharmacy

(5-046) Leading Factors of Pharmacy Technician Turnover Intention in Nebraska

(5-207) Assessing Standardized EVS Policies and Competencies to Enhance Safety and Compliance for Sterile and Hazardous Compounding Across Hospital Facilities

(5-208) Investigating the role of clinical pharmacy services in reducing readmission rates for high risk patient population

(5-228) Optimizing Ophthalmic Medication Formularies: A Comprehensive Evaluation of Therapeutic Classes

(5-246) Faculty Engagement, Perspectives and Barriers to Mentoring Student Research Projects

(5-279) Enhancing Electronic Health Record (HER) Reliability: A Replicable Approach for Healthcare Downtime Management

(6-064) Estimating Impact of Oral Linezolid Used for Selected Infections

(6-083) Review of the Transition from Weight-Based Dosing to a Fixed Dose Regimen of Four-Factor Prothrombin Complex Concentrate at a Community Hospital

(6-118) Analysis of Medications Prescribed and Dispensed at Columbus Free Clinic

(6-131) Examining The Underinsured/At-Risk Populations: Impact and Opportunities for Infusion Clinics

(7-014) Cost Evaluation of Piperacillin/Tazobactam IV Preparation Formulary Changes

(7-089) Narcotic Delivery Verification Pilot at Cook Children's Medical Center

(7-160) Assessment and Optimization of Neonatal Sepsis Intravenous Antibiotic Turnaround Time at an Academic Teaching Hospital

(7-187) Refine Mayo Clinic Pharmacy Residency Recruitment Approach

(7-227) Piloting Hospital At Home Pharmacy Services Within An Integrated Health System

(7-248) Medication Procurement Optimization at UVA Health Children’s (UVAHC) Related to Insurance Mandated Care Steerage in the Ambulatory Setting

(7-262) Quantification of the Home Infusion Pharmacist’s Workload through a Review of Pharmacists’ Tasks in an Electronic Health Record (EHR)

(7-367) Measuring Pharmacist Order Verification Workload Through an Electronic Health Record at a Large Academic Medical Center Based on Pharmacological Class

(8-001) Financial Impact of a Zero Co-Pay Generic Pharmacy Benefit Design

(8-002) Development of a Standard Prescription Supporting Program for High-Alert Parenteral Medications to Improve Patient Safety

(8-003) System Integration of an Aligned Pharmacy and Therapeutics Committee, Policies, and Procedures Across Managed Entities

(9-062) Trends in Non-Formulary Medication Requests - A Retrospective, Multicenter, Observational Study

(9-089) Cost Analysis of Antidotes and Antivenoms Among Patients Presenting with Overdose or Envenomation Utilizing Various Purchasing Methods

(9-170) Optimization of the New Medication Onboarding Process at a Large Academic Medical Center

(9-258) Evaluating the Efficacy of an Evidence Based Scoring System to Determine a Novel Formulary Status Classification for Therapeutics Undergoing Formulary Consideration

(9-344) The Effect of Drug-Specific Questionnaires on Prior Authorization Processing Time for Electronic Requests in HealthPlan Marketplace Populations Requiring Biologic Therapy for Asthma Treatment

(9-403) Addressing the Pharmacy Technician Shortage: The Role of a Flexible Float Pool

(9-454) Evaluation of the Impact of a Pharmacy-Coordinated Glycemic Management Program

(9-459) Assessment of the Medication Repackaging Process at the BayCare Central Pharmacy

(10-007) Impact of Recruitment-Focused Strategies in Improving Diversity, Equity, Inclusion, and Belonging in a Pharmacy Residency Program

(10-017) Evaluation of a Pharmacist-Led Education Service on Hospital Consumer Assessment of Healthcare Providers and System (HCAHPS) Scores

(10-147) Impact of a Pharmacist-Managed Quality Improvement Initiative on the Cost Savings Associated with Dose Rounding Oncology Medications

(10-272) Enhancing Antimicrobial Stewardship Through Health-System Integration: A Multidisciplinary Approach

(10-403) Development of a competency-based orientation (CBO) model to assess education, training, and proficiency in order verification for inpatient pharmacists

(11-111) Implementation of Automated Dispensing System Regulated Insulin at Mississippi Baptist Medical Center

(11-250) Evaluation of Operational and Financial expenditure of premixed versus compounded Vasopressin

(12-062) Optimization and Compliance of Medications with Risk Evaluation and Mitigation Strategies (REMS) Program Designation at Novant Health

(12-119) Impact of a pharmacy technician in an outpatient clinic on hospital cost reductions and patient outcomes

(12-180) Evaluation of Current Credentialing and Privileging Standards for Inpatient Pharmacists

(12-222) Financial Impact of Clinical-Pharmacist-Led Medication Therapy Management Clinic in the Context of 340B Drug Pricing at a Regional Health System

(12-232) Assessment and Validation of Clinical and Operational Pharmacist Workflow and Productivity Model at a Medium-Sized Community Hospital

(12-324) Evaluating Dispensing Activities and Workflow of Current Omnicell XR2 and Swisslog PillPick Robots to Successfully Decommission Swisslog PillPick Robot

(12-413) Profitability of 340B Contract Pharmacy

(12-444) Implementation of a Satellite Sterile Compounding Pharmacy within an Infusion Center

(12-445) Health System Medication Waste Management through Utilization of Centralized Distribution System

(13-039) Analysis of Hospital Pharmacy Workflow for Automated Dispensing Cabinet Medication Delivery

(13-047) Evaluation of Hospital Pharmacy Pricing and Utilization Trend on Hospital Expenses: Prediction versus Reality

(13-053) Evaluation of the Impact of the Pharmacy Technician Shortage on Pharmacy Workflow and Resources

(13-086) Diversion Prevention: The Role of Technology in Identification of High-Risk Persons of Interest

(13-115) Effect of a Health System Funded Prescription Assistance Card Program for Underinsured Patients

(13-317) Pharmacy Integration into Health System Revenue Cycle Processes

(13-327) Implementation of an inpatient pharmacist credentialing and privileging process

(13-365) Optimizing Standard Operating Procedures to Improve Pharmacy Staff Workflow and Patient Care

(13-367) Implementation of a Virtual Carousel at a Community Hospital

(13-374) Infusion clinic revenue integrity: optimization of the medication prior authorization process

(13-377) Infusion Clinic Revenue Integrity: Reconciling Medical Necessity Criteria

(13-380) Transitional Care Protocol for Patients Needing Short Course Infusions or Injectables

(13-382) Standardization of Pharmacist Population Health Workflow and Metrics Reporting

(1-002) Pharmacist-Managed Inhaled Corticosteroid De-Escalation in Patients with Stable COPD at a Veterans Affairs Medical Center

(1-003) Evaluation of Methotrexate Prescribing Practices in a Veterans Affairs Health Care System

(1-004) Impact of an Addition of a Clinical Pharmacist to a Weight Management Clinic at a Military Treatment

(1-024) Implementation of Empagliflozin in Patients with Pre-Existing Heart Failure with Reduced Ejection Fraction

(1-048) Impact of an Interdisciplinary Pharmacy-Based Weight Loss Program

(1-049) Comparative Effectiveness of FDA-Approved Injectable and Non-Injectable Pharmacologic Medications for the Treatment of Obesity within a Federally Qualified Healthcare Center

(1-050) Impact of Pharmacist-Led Smoking Cessation Interventions on Tobacco Cessation Rates in a Federally Qualified Health Center

(1-052) Evaluation of pharmacist led weight management medication management versus standard follow up

(1-053) Evaluation of Vitamin B12 Monitoring in Veterans on Long-term Metformin Therapy at a Single Department of Veteran Affairs Medical Center

(1-061) Improving Screening Process for Chronic Kidney Disease (CKD) in Veterans with Hypertension

(1-064) Retrospective Evaluation of the Appropriateness of Semaglutide Continuation for Weight Loss among a Veteran Population

(1-072) Impact of Primary Care Pharmacists on Heart Failure Management

(1-076) Evaluation of Clinical Pharmacy Technician Workflow Modifications in the Direct Oral Anticoagulant Dashboard

(1-079) Melatonin Medication Use Evaluation at VA Connecticut Healthcare System

(1-087) Evaluation of retinal exams and hemoglobin A1c monitoring in a Veterans Affairs population treated with Ozempic (semaglutide) for type 2 diabetes

(1-090) Evaluation of the Utilization, Efficacy, and Safety of Weight Loss Medications in a Veterans Affairs (VA) Population

(1-095) Impact of Expanding Pharmacist Scope of Practice Through Management of Gout, Hypothyroidism, and Diabetic Neuropathy in Primary Care at a Veterans Affairs Medical Center

(1-099) Medication Use Evaluation and Expansion of Weight Loss Management into Clinical Pharmacy Practitioners’ Clinics at James A. Haley Veterans’ Hospital

(1-108) Weight and Glycated Hemoglobin Reduction with Glucagon-Like-Peptide-1 Receptor Agonists According to Weight Category in Veterans with Type 2 Diabetes

(1-110) Evaluation of Insulin Dose Percent Change After Initiation of Semaglutide in Patients Diagnosed with Type 2 Diabetes Mellitus at North Florida/South Georgia Veterans Health System

(1-112) Incidence of statin-associated musculoskeletal symptoms in Veterans with altered SLCO1B1 phenotype

(1-114) Comparison of Prophylactic Anti-inflammatory Agents Initiated Concomitantly With Urate-Lowering Therapy for Gout Prophylaxis

(1-116) Retrospective review of patients receiving concomitant allopurinol and thiazides with history of gout and/or hyperuricemia

(1-122) Evaluation of Dose-Dependent Relationship Between Mirtazapine and Weight Gain

(1-136) Pharmacist Led Continuous Glucose Monitor Initiation: Time Spent and Impact on Veteran Care Before Transitioning Management to the Primary Care Team

(1-138) Deprescribing Sulfonylureas in Patients Above the Age of 65 Within the Boise VA Medical Center

(1-141) Initiative to Increase Vaccination Rates of Veterans on Immunocompromising Rheumatologic Medication

(1-142) Evaluation of Metformin Prescribing Practices in Patients with Prediabetes or History of Gestational Diabetes Within the Women’s Wellness Clinic at the Boise VA Medical Center

(1-143) Implementation of a Syringe Services Program at Two Veterans Affairs Medical Centers

(1-145) Assessing Tobacco Cessation Success Rates and Pharmacist Involvement at a Federal Health Care Center (FHCC)

(1-146) Human immunodeficiency virus (HIV) Incidence and Pre-Exposure Prophylaxis (PrEP) prescribing trends within a Federal Health Care Center

(1-164) Medication Use Evaluation of the Safety and Effectiveness of Empagliflozin

(1-167) Evaluation of a pharmacist-driven inhaled corticosteroid de-escalation intervention in veterans

(1-173) Impact of Pharmacy Intervention on Lipid Lowering in Veterans with ASCVD Enrolled in the Veterans Affairs Lipid Optimization Reimagined Quality Improvement Program (VALOR-QI)

(1-176) Assessing Tolerability Upon Switching From Maximum Dose Liraglutide to Semaglutide for Obesity

(1-181) Impact of a Resident Run Weight Management Clinic on Health Outcomes in a Primary Care Setting within the Veterans Health Administration

(1-186) Increased Access to Suboxone in the Emergency Department with a Pharmacist-Led Initiative

(1-188) Evaluating Provider Acceptance of Pharmacy Recommendations to Deprescribe Sulfonylureas in Patients at Elevated Hypoglycemic Risk

(1-197) Achievement of guideline directed therapy of target dosing in primary care Veterans with heart failure reduced ejection fraction at G.V. Sonny Montgomery VA Medical Center

(1-201) Evaluation of Clinical Pharmacist Medication Management Within the MOVE! Weight Management Program for Veterans

(1-202) Incidence of clinically significant worsening or new onset diabetic retinopathy after semaglutide or dulaglutide initiation

(1-213) Clinical and Economic Impact of Weight Loss Medications in a Veteran Population

(1-218) Implementation of an Osteoporosis Screening Tool for Male Veterans in the Ambulatory Care Setting at VASNHCS

(1-219) Impact of Direct-to-Consumer Education on Treatment of Alcohol Use Disorder Within a Veteran Population

(1-226) Evaluating the effect of glycemic control in patients transitioning from liraglutide to semaglutide at a Veteran Affairs Healthcare System

(1-227) Implementing the Use of Continuous Glucose Monitoring Devices into a Pharmacist-Led Diabetes Management Clinic

(1-228) Development and Assessment of a Collaborative Practice Agreement for Integration of Heart Failure Pharmacy Services into Anticoagulation Clinic

(1-232) Improving heart failure prescribing practices through physician education and clinical decision support system updates in an American Indian/Alaska Native population

(1-239) Effectiveness of Continuous Glucose Monitoring Systems in A1c Reduction in Patients with Type 2 Diabetes Mellitus at Northport Veteran’s Affairs Medical Center (VAMC)

(1-247) Impact of Pharmacist Interventions in Veterans with Chronic Obstructive Pulmonary Disease

(1-262) Implementation of a Pharmacist-Led Initiative to Deprescribe Aspirin for Primary Prevention in a Geriatric Veteran Population

(1-263) Impact of a Pharmacist-Led Weight Loss Medication Management Service in a Veteran Community

(1-264) Pharmacist-Led Initiative to Deprescribe Tramadol and Semi-Synthetic Opiates in Veterans with Altered CYP2D6 Metabolism Based on Pharmacogenomic Test Results

(1-266) Evaluation of the Impact of a Pharmacy-Based Chronic Obstructive Pulmonary Disease (COPD) Quality Improvement Project at a Rural Indian Health Service Facility

(1-270) Pharmacist Transitions of Care Pilot at the Cincinnati Veterans Affairs Medical Center

(1-277) Implementation of a Pharmacist Managed Remote Monitoring Hypertension Program for American Indians and Alaska Natives in a Rural Ambulatory Care Tribal Health System.

(1-278) Pharmacist's review of the efficacy and safety of semaglutide in a population of type-2 diabetic Native Americans at a rural Indian Health Service facility

(1-282) Evaluation of a Pharmacist-Ran Tobacco Cessation Clinic Quit Rate Before and After Varenicline Recall

(1-283) Pharmacist Interventions in Patients with COPD Utilizing the COPD Dashboard at the Oklahoma City Veterans Affairs Health Care System: A Quality Improvement Project

(1-285) Assessment of Long-Term Success Rates at a Pharmacist-Run Tobacco Cessation Clinic Over a 10-Year Period.

(1-295) Impact of Clinical Pharmacist Interventions on Potentially Overbasalized Insulin Patients

(1-313) Evaluation of Semaglutide 1 mg Injection versus Semaglutide 2 mg Injection in the Management of Type 2 Diabetes Mellitus: A Cost versus Health Benefit Analysis

(1-314) Medication Use Evaluation of Cholinesterase Inhibitors and Memantine in Home Based Primary Care

(1-316) Evaluation of Insulin Glargine-yfgn in Veterans for the Treatment of Type II Diabetes Mellitus at the Providence Veterans Affairs Medical Center

(1-318) Implementation of Gout Guideline Directed Medical Therapy with Allopurinol Optimization Based on Uric Acid Levels in a Veterans Affairs Ambulatory Care Outpatient Clinic

(1-324) Developing and Implementing Pharmacist Initiated Treatment for Acute Infections

(1-329) Outcomes of Pharmacist Utilization of Population Health Management Tools to Identify and Treat Patients with Uncontrolled Hypertension

(1-332) Outcomes of Pharmacist-led Tobacco Cessation Clinic in a Veteran Population

(1-336) Suicide-Related Events when using Glucagon Like Peptide 1 Receptor Agonists in a Veteran Population with a History of Mental Health Conditions

(1-341) An Educational Series on Hypertension Provided by a Pharmacist to Primary Care Teams to Improve Blood Pressure Control in Veterans with Uncontrolled Hypertension

(1-347) Implementation of the Hypoglycemic Safety Initiative at a Veterans Affairs Community Based Outpatient Clinic

(1-348) Implementation of a Transitions of Care (TOC) Pharmacy Service in an Outpatient Based Veterans Affairs Healthcare Facility

(1-351) Development of an Equity-Focused Assessment Template Addressing Disparities of Blood Pressure Control for Black Veterans within the Salt Lake City VA Health Care System (SLCVAHCS)

(1-352) Assessment of Ordering and Education Practices for New Continuous Glucose Monitor (CGM) Starts by Pharmacists at VA Salt Lake City Healthcare System (VASLCHCS)

(1-363) Improving Inhaler Technique Among Native Americans in an IHS Outpatient Clinic With the Aid of an Aerosol Inhalation Monitor

(1-364) Efficacy of GLP-1 receptor agonist therapy in achieving weight loss over 3, 6, and 12 months in veterans

(1-368) Retrospective Analysis of A1C Changes and Safety Outcomes in Veterans Transitioned to Continuous Glucose Monitoring From Self-monitoring

(1-378) Cardiovascular Risk Reduction Using Statins in Patients with Type 2 Diabetes Mellitus at a Rural Veterans Affairs Healthcare System

(2-011) Impact of Pharmacist Intervention and Health-System Affiliated Outpatient Pharmacy Filling on Patients’ Diabetes Control at an Outpatient Ambulatory Care Clinic

(2-022) The Diabetes Prevention Program to Treat Overweight and Obesity (DPP-TOO)- Results of an 18-week pilot

(2-025) Clinical and Financial Outcomes of a Pharmacist-Led Continuous Glucose Monitoring Clinic in a Federally Qualified Health Center

(2-042) Clinical Inertia Benefits of Adding a Pharmacist to the Outpatient Collaborative Care Team in Primary Care: A Focus on Type II Diabetes Mellitus.

(2-043) Evaluation of GLP-1 RA injectable technique in a small cohort of patients

(2-058) Social Determinants of Health as a Predictor of Shared Decision-Making Regarding Prostate Specific Antigen Testing

(2-071) Naloxone: A Pain to Co-Prescribe? Evaluating naloxone co-prescribing practices for patients at an increased risk of opioid overdose at a federally qualified health center.

(2-085) Implementation of Wellness Clinics in Collaboration with Pharmacists and Quality Team to Improve Quality Measures

(2-093) Efficacy and Safety of Dabigatran Compared to Apixaban and Rivaroxaban in Patients with VTE and BMI ≥40 kg/m2 and/or Weight ≥120kg

(2-100) Hemoglobin A1c Reduction by Pharmacist-Led Interventions in an Ambulatory Care Clinic

(2-107) Self-measured Blood Pressure Monitoring in a Spanish and English Language-Concordant Setting: A Retrospective Chart Review

(2-110) Evaluating the Conjunction of using both CGM and Fructosamine for Monitoring Glycemic Control in African Americans Who Have Type 2 Diabetes

(2-171) Effectiveness of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RA) for Weight loss in Non-Diabetic Patients

(2-179) Automated Insulin Delivery (AID) use in Pregnancies Complicated by Type 1 Diabetes

(2-183) Risk Factors of Gastroparesis with Concurrent Use of GLP-1 Receptor Agonists

(2-193) Prescription Medications and Physical Therapy Practice Considerations in Traumatic Brain Injury

(2-235) Utilization of Patient Outreach and Educational Materials to Improve Health Education and Literacy in a Rural and Underserved Population

(2-237) Assessing the appropriateness of low intensity statin usage

(2-263) The Impact of Insulin Biosimilars on Diabetes Care: A Review

(2-265) InsuLINK: Enhancing Insulin Adherence for Optimal Diabetes Management

(2-286) The impact of remote patient monitoring in addressing social determinants of health in patient outcomes.

(2-297) Impact of Enhanced Contact on Time-in-Therapeutic Range in Self-Testing Warfarin Patients with Home Point-of-Care International Normalized Ratio Devices

(2-310) Frequency and Timing of Lipid Labs for the Management of Type 2 Diabetes in American Indian Adults Compared to Practice Guidelines

(2-321) Effect of Metformin on Depressive Episodes in Individuals with Major Depressive Disorder: A Retrospective Cohort Study

(2-322) Increasing Utilization of Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitors in Congestive Heart Failure Patients

(2-340) Respiratory syncytial virus (RSV) Vaccine Prescribing in an Outpatient Internal Medicine Clinic

(2-353) Relationship Between Glycemic Control and Weight Loss with Tirzepatide Injection, The First and Only Dual GIP/GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes

(2-373) Assessment of the Enoxaparin Prescribing Following the CHEST Periprocedural Guideline Update

(2-375) A Comparison of Patient Assistance Approvals During and Post-SARS-CoV-2 at an Academic Medical Center

(3-005) Comparison of weight loss diabetic medication prescribing and self-reported obesity prevalence rates in the United States in 2021

(3-011) Identifying Hepatitis C in Patients with Opioid-Associated Diagnoses for Enrollment into Pharmacist-Led Hepatitis C Management Program

(3-012) Optimizing Heart Failure Care: A Retrospective Analysis of GDMT Adherence at East Hawaii Health Clinic

(3-023) 2020 Diabetes Deaths and Medicare Statin Prescription Rates

(3-078) Impact of a Pediatric-Trained Clinical Pharmacist in Pediatric Outpatient Kidney Transplant Clinic

(3-115) Evaluating the Efficacy of a Pharmacist and Nurse-Led Heart Failure Clinic in Optimizing Guideline-Directed Medical Therapy (GDMT) in Comparison to General Cardiology Outpatient Offices.

(3-123) Community Health Center Patient and Provider Perspectives of the Helping Build Healthy Communities Initiative: A Qualitative Study

(3-126) Evaluation of a Cardiology Ambulatory Care Pharmacist-Led Service on Adherence to Antiarrhythmic Drug Monitoring

(3-137) Patients' Level of Knowledge of Drug-Drug Interactions in Saudi Arabia: A Cross-Sectional Study

(3-165) Evaluation of Pharmacist Managed Type 2 Diabetes Mellitus in the Primary Care Setting

(3-168) Evaluating the Implementation of a Silent Best Practice Alert and Patient Outreach Initiative to Improve Blood Pressure Control in the Ambulatory Setting

(3-245) Transforming Type 2 Diabetes Management: Optimizing Time in Range with the Use of a Continuous Glucose Monitor

(3-259) Targeted Outreach to Increase Preventative Healthcare Education at Title 1 Baltimore City Elementary Schools

(3-261) Impact of a Clinical Pharmacist-Led Comprehensive Diabetes Management Program on Diabetes Outcomes at a Federally Qualified Health Center

(3-267) Successful Implementation and Improved A1C with a Bolus Only Insulin Patch Using Regular 500 unit/milliliter Insulin

(3-269) Treatment and Management of a Level 3 Hypoglycemic Reaction at a Primary Care Pharmacy Visit

(3-273) Clinical management of Steroid-induced Hyperglycemia in an outpatient setting: A case report

(3-280) Evolocumab in Statin-Intolerant Patient

(3-286) Prolonged Adverse Effects of Dextroamphetamine-Amphetamine with Concurrent use of Semaglutide

(3-293) Effect of Bedtime Dosing of Antihypertensive Medication on Cardiovascular Outcomes: A Bayesian Meta-Analysis of Prospective Randomized Control Trials

(3-299) Collaborative Transitions of Care in Latent Autoimmune Diabetes in Adults (LADA): A Case Report Highlighting the Role of Pharmacists

(3-302) The Treatment of "Diabesity" a Case Study

(3-303) A case of highly significant improvement in glycemic control and weight loss switching from semaglutide to tirzepatide

(3-308) Exploring Potential Benefit of CGM in Uncontrolled Type 2 Diabetes patients: A Case Report

(3-315) Semaglutide as a Potential Treatment for Binge Eating Disorder in a Patient with Class 1 Obesity: A Case Report

(3-338) Overlooked Cause of Hyperglycemia in End-Stage Renal Disease: A Case of Polypharmacy

(3-342) Improvement in Continuous Glucose Monitor Time in Range Targets in Patients switched from Glucagon-like Peptide-1 Receptor Agonist to Tirzepatide Therapy

(3-343) Patient knowledge and perceptions of insulin biologics and biosimilars

(3-347) Long-Term Effect of Pharmacist-Led Diabetes Distress Interventions on Glucose Management and Weight Among People with Type 2 Diabetes

(3-370) Assessing the Impact of Implementing a Meds-to-Beds Pilot Service on Patient and Staff Satisfaction

(3-372) Real-World Clinical Outcomes for Patients Prescribed Liraglutide for Weight Loss by their Primary Care Provider at a Large Academic Medical Center

(3-375) Increasing use of SGLT2 inhibitors in nephrology clinics at an academic medical center

(3-387) Clinical Pharmacist Outpatient Visits as Part of Pediatric Cystic Fibrosis Care: From Pandemic Lockdown to Community Reopening

(4-004) Assessment of Blood Pressure and Body Mass Index in Low-Income Uninsured Patients with Diabetes in a Community Free Clinic

(4-006) Impact of Clinical and Specialty Pharmacy Services on Hepatitis B Virus Treatment Optimization

(4-007) Impact of an Ambulatory Care Pharmacist-Led Medication Refill Management Service in Primary Care

(4-008) Alpha-Fetoprotein Improvement and Association of Comorbidities Treatment Follow-Up in Patients with Chronic Liver Diseases

(4-009) Analysis of an Influenza Vaccination Quality Improvement Initiative in a Rural Federally Qualified Healthcare Center

(5-024) Review of Medication Classes and Reasons for Decline in Medication Adherence Rates: A Population Health Approach

(5-026) Pharmacist-Led Hypertension Management Outcomes in an Ambulatory Care Setting

(5-052) Evaluating the Impact of a Student Pharmacist-led Model for Initiating Statin Therapy in Patients with Type 2 Diabetes.

(5-147) Controlling Hypertension in a Federally Qualified Health Center: Baseline Compliance with Guideline-Based Pharmacotherapy in a Randomized-Controlled Study

(5-169) Association of High-Risk Comorbidities in Patients with a Diagnosis of Gender Dysphoria in New Mexico

(5-229) Evaluation of Daily Multivitamin Use and Cognition in 911 World Trade Center Responders

(5-240) Evaluation of Guideline-Directed Medical Therapy and Blood Pressure Control in Patients Enrolled in a Pharmacist-Led Heart Failure Remote Patient Monitoring Program

(5-252) Comparison of Intranasal Corticosteroids to Intranasal Corticosteroids Plus Intranasal Antihistamines on 9/11 Responders with Chronic Rhinitis

(5-262) Knowledge, Attitudes, and Awareness of Climate Change and Health Among Pharmacy Students

(5-306) Predictors of Healthcare Utilization Within 30 Days of Hospital Discharge in a Primary Care Patient Population

(5-312) Utilizing Professional Continuous Glucose Monitors in Clinical Decision Making to Improve Glycemic Control

(6-019) Pharmacy Dashboard Review and Optimization of High-Cost Medications at a Family Medicine Clinic

(6-034) Diabetes Mellitus, Hypertension, and Coronary Artery Disease Outcomes After Clinical Pharmacist Intervention in the Primary Care Setting

(6-045) Evaluation of Pharmacist Impact on Hypertension Control in a Family Medicine Practice: A Health Disparity Quality Improvement Interdisciplinary Intervention

(6-055) Insulin Overbasalization in Family Medicine Patients

(6-058) Review of Glucagon Prescribing for Patients Presenting to the Emergency Department for Hypoglycemia

(6-061) Off-Label Use of Concentrated Insulin Lispro U-200 in Type 1 and Type 2 Diabetes

(6-062) Assessing the Effectiveness of a Pharmacist-Led Hepatitis C Virus (HCV) Program for Low income, Under- and Uninsured Patients at a Free Clinic

(6-070) Self-Measured Blood Pressure Monitoring Program: Clinical-Pharmacist Led Blood Pressure Management at a Federally Qualified Health Center

(6-154) Limitations and barriers of continuous glucose monitors in the elderly population

(6-160) Transitioning Veterans Between Two Formulations of Insulin Glargine U-300 Based on Cost and Safety Standpoints

(6-173) Impact on HbA1c and Analysis of Interventions in a Pharmacist-Led Diabetes Service within an Endocrinology Clinic

(6-176) Assessment of a clinical pharmacist-run nirmatrelvir/ritonavir prescribing service

(6-181) Impact of Drug Shortage on Medication Choice for Therapy of Attention Deficit Hyperactivity Disorder

(6-189) Outcomes of an Initiative to Address Barriers to Semaglutide for Diabetes Usage at a Federally Qualified Health Center

(6-199) Nutritional Literacy Among Healthcare Professionals

(6-203) Are providers targeting appropriate cholesterol goals for secondary ASCVD prevention in patients who also have diabetes?

(6-222) Weight Loss Medication Outcomes Across BMI Classifications in Primary Care

(6-228) Dose optimization of glucagon-like peptide-1 agonists in primary care

(6-229) Beers medication utilization and deprescribing in older adults with a history of fall

(6-244) Assessing the Clinical Outcomes of Outpatients with Type 2 Diabetes Whose Care is Being Managed by Ambulatory Pharmacists

(6-254) Implementation of a Behavioral Goal Assessment Tool for Pharmacist-led Diabetes Education Encounters

(6-266) Increasing access to appropriate emergency contraception at the Shadyside Family Health Center

(6-267) Hypoglycemia Quality Improvement

(6-291) Pharmacist-led Interdisciplinary Cardiovascular Risk Reduction for People Living with HIV: A Prospective Quality Improvement Cohort Intervention

(6-308) Assessing the Pharmaceutical-Care Needs of People Living with Parkinson’s Disease Through the EMPOWER PD Clinics - An Interdisciplinary Model of Care that Integrates Pharmacy Services.

(6-321) Evaluation of factors associated with uncontrolled hypertension in a Medicare Accountable Care Organization (ACO) population

(6-332) Diabetic Retinopathy Associations with Antidiabetic Agents: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)

(7-001) Feasibility of Finerenone Initiation in an Uninsured Patient Population

(7-006) Assessing the Impact of Clinical Pharmacy Services in a Residential Women’s Substance Use Facility

(7-027) Impact of Hospitalization on Continuation of SGLT-2 Inhibitors for Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease, or Heart Failure in Type 2 Diabetes Mellitus Patients

(7-028) Impact of Hospitalization on Continuation of GLP-1 Agonists for Atherosclerotic Cardiovascular Disease in Type 2 Diabetes Mellitus Patients

(7-033) Evaluating the Impact of Clinical Pharmacists in Facilitating Access to Diabetes Medications using Medication Assistance Programs for Underinsured and Uninsured Patients

(7-067) Kidney Health Discussions During Clinical Encounters with Acute Kidney Injury Survivors: a Videographic Analysis

(7-074) Early Initiation of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Kidney Transplant Recipients

(7-084) Evaluation and Effectiveness of Glucagon-Like Peptide-1 (GLP-1) Therapies and the Conversion to Dual Incretin Therapy With Glucose-Dependent Insulinotropic Polypeptide/ Glucagon-Like Peptide-1 (GIP/ GLP-1)

(7-087) Medication Adherence Based on A1c Trends in Diabetic Patients on a Patient Assistance Program

(7-113) Evaluation of the Clinical Impacts of a Specialty Clinical Pharmacist on Time-to-Therapy in the Ambulatory Outpatient Dermatology Clinic

(7-126) Glucagon-like Peptide-1 Receptor Agonist Therapy in a Patient with Type 2 Diabetes with an Intragastric Balloon for Weight Loss

(7-135) Evaluating the Impact of a Pharmacist-Led Virtual Hypertension Clinic on Blood Pressure Control Compared to Standard Care

(7-150) Pharmacist Intervention to Improve Statin Therapy in Persons with Cardiovascular Disease (SPC) and Statin Use in Persons with Diabetes (SUPD)

(7-155) The Evaluation and Comparison of Glucagon-Like-Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Agonists in Patients with Type 2 Diabetes in an Ambulatory Care Setting

(7-157) Hemoglobin A1C (HbA1c) Reduction with a Pharmacist - Run Continuous Glucose Monitoring (CGM) Service in a Federally Qualified Health Center (FQHC)

(7-169) COVID-19: Race and Ethnicity Influence on Type 2 Diabetes

(7-171) Type II Diabetes Mellitus and COVID-19: A Case Series Exploring Insulin Management in Patients from Two Family Medicine Clinics

(7-237) Impact of Pharmacist Led Quality Improvement Initiative on Statin Adherence in Non-Caucasian or Female Veterans with Diabetes or Cardiovascular Disease

(7-246) Optimizing Diabetes Care: Impact of a Pharmacist-Led Clinic on Insulin Reduction with Concomitant Use of Incretin Mimetics.

(7-263) Impact of Pharmacy Students as Lifestyle Coaches on Delivery of National Diabetes Prevention Program

(7-272) Analysis of Provider Literacy and Prescribing Practices for Insulin Delivery Systems and Compatible Continuous Glucose Monitors

(7-274) Performance of the MAUQ-en-US in a Diverse, Urban Sample of Patients with Chronic Diseases

(7-283) Initiation of a Pharmacist-Led Continuous Glucose Monitor (CGM) Pro Service in an Outpatient Setting

(7-338) Characteristics of Patients Referred to a Family Medicine Pharmacist Run Clinic

(7-365) Patient Needs Assessment: Developing a Tailored Diabetes Self-Management Education and Support Program

(7-370) Slimming Down Smarter: Characterization of Weight Loss Consults to Primary Care Clinical Pharmacists in an Academic Healthcare System

(7-375) Evaluating the Efficacy of a Pharmacist-Led Intervention to Improve Hypertension Management in Primary Care at UW Health

(7-381) Introduction of Transitions of Care Pharmacy Services to the Behavioral Health Unit

(7-383) Targeted Ambulatory Pharmacist Deprescribing for Short-term Stay Patients Upon Skilled Nursing Facility Admission

(7-389) The Role of Pharmacy Students in Diabetes Education and Continuous Glucose Monitoring

(8-004) Assessment of Hemoglobin A1C, Urine Microalbumin/creatinine, and Lipids Management in Low-Income, Uninsured Patients with Diabetes in a Community Free Clinic

(8-005) Impact of Pharmacist-Led Interventions on Deprescribing of Low-Dose Aspirin for Primary Prevention

(8-006) A Retrospective Review of Glucagon Like Peptide-1 Receptor Agonists Use and Incidence of Retinopathy in an Adult Medicine Ambulatory Care Clinic

(8-007) Student Pharmacists’ Attitudes and Knowledge of Social Determinants of Health in Ambulatory Care Experiential Setting Before and After Interprofessional Collaboration with a Community Health Worker

(8-008) Implementation of an Interprofessional Electronic Consult for the Management of Postpartum Hypertension (PPHTN)

(8-079) Identifying Prescribing Quantity and Trends of Potentially Inappropriate Medications in a Rural Federally Qualified Health Center Patient Centered Medical Home

(9-003) Evaluation of Pharmacy and Social Work Interventions Made Within an Innovative, Ambulatory Care-Based Transitions of Care Service

(9-004) Evaluation of the impact of the addition of group education to an established employer-based weight loss service

(9-005) Assessment of the impact of a pharmacist-led pharmacogenomics service on statin utilization in Veterans with risk factors for ASCVD

(9-040) Medicare Annual Wellness Visit Quality Measures and Provider Reimbursement: A Comparison of In-Person and Telehealth Modalities

(9-041) Evaluating the Usage and Titration of Glucagon-like Peptide-1 Receptor Agonists in Patients with Uncontrolled Type 2 Diabetes Mellitus

(9-047) Impact of an Ambulatory Care Pharmacist in a Pediatric Outpatient Clinic

(9-072) Revised Workflow for Pharmacist-Led Hepatitis C Treatment Program at a Federally Qualified Health Center

(9-104) Assessing Impact of Clinical Pharmacist-Led Interventions to Achieve Blood Glucose, Blood Pressure, and Cholesterol Goals in Patients with Type 1 or Type 2 Diabetes Mellitus

(9-105) Assessing Optimization of Provider-Initiated DOAC Stroke Prophylaxis in Patients Diagnosed with Atrial Fibrillation

(9-146) Pharmacist Partnership with Clinics at Riverside University Health Systems to Improve Adult Diabetes Management

(9-157) Development and Impact of a Pharmacist-Driven ASCVD Prevention and Treatment Protocol in the Primary Care Setting

(9-158) Evaluating the Clinical and Financial Impact of Pharmacist Interventions in a Chronic Kidney Disease Program at Stanford Primary Care

(9-164) Implementation of a Pharmacogenomics Consult Service at a Rheumatology Clinic

(9-173) Implementation of Referral Criteria to Improve Access to Addiction Medicine Service

(9-174) The Effectiveness of Prior Authorization Removal on SGLT2 Inhibitor Utilization

(9-175) Sweet Success: Evaluating the Effect of Continuous Glucose Monitoring on Hemoglobin A1c in Patients with Diabetes

(9-193) Development and Implementation of a Pediatric Ambulatory Care Pharmacist Managed Service

(9-202) Utilization of Ambulatory Pharmacy Services and Their Overall Impact on Patient Care within Internal Medicine Clinics

(9-227) Evaluation of HbA1c in Patients Followed by a Pharmacist and Pharmacy Liaison in an Endocrinology Clinic

(9-231) Comparison of a pharmacist-led outpatient anticoagulation clinic to a prescriber-led clinic on the management of direct-acting oral anticoagulants (DOACs) at UConn Health

(9-242) Impact of Pharmacist-Led Type 2 Diabetes Mellitus Management on Hemoglobin A1c Outcomes in Patients with Uncontrolled Diabetes in a Primary Care Clinic

(9-247) Impact of Pharmacist Intervention on Statin Use in Adult Internal Medicine Patients with Diabetes

(9-248) Impact of Pharmacist Intervention on Screening Patients with Diabetes for Chronic Kidney Disease (CKD) and the use of guideline directed therapy

(9-268) Evaluation of Monitoring Parameters for Rituximab in the Ambulatory Care Setting

(9-269) Improving Immunization Rates of Patients Prescribed Specialty Immunomodulating Medications in a Large Academic Medical Center

(9-299) Evaluating ambulatory care pharmacists' impact on access to care, fiscal outcomes, chronic disease therapy management, and care quality through implementation of transitions of care

(9-301) Comparison of sodium zirconium cyclosilicate versus sodium polystyrene sulfonate for the management of acute hyperkalemia

(9-311) Impact of Smoking Cessation Intervention by Clinical Pharmacist in Federally Qualified Centers; an Outpatient Setting

(9-314) Bad to the Bone: Medication Use Evaluation on Prolia® (denosumab) in Patients with Osteoporosis

(9-318) Evaluating the impact of a pharmacist-led refill management program on outpatient provider visit rates and medication adherence at a large health system

(9-424) Change in HbA1c in Type 2 Diabetes Patients on Real-Time Continuous Glucose Monitoring (CGM) Versus Routine Care

(9-436) Financial Performance and Reimbursement of Co-Funded Faculty Pharmacist-Provided Services in a Privately Owned Family Medicine Practice

(9-437) Pharmacist-Led Screening for Metabolic Dysfunction-Associated Liver Disease Within a Family Medicine Clinic Using the FIB-4 Index in Patients 65 Years or Older.

(9-465) Clinical and Economic Impact of Pharmacist-Led Interventions in Reducing A1C among Indigent Patients at Transitions of Care Outpatient Clinic: A Value-Based Care Approach

(9-474) Heart Failure Guideline Directed Medication Therapy Utilization With a Transitions of Care Pharmacy Service and Impact On Skilled Nursing Facility patients

(10-020) Prescribing practices of the four pharmacological pillars of heart failure with reduced ejection fraction therapy in an integrated healthcare system

(10-022) Evaluation of factors that led to the achievement of A1c goal in patients with type II diabetes

(10-049) Statin Reinitiation in High-Risk Patients with a Documented Statin Allergy

(10-070) Impact of a Novel, Individualized Approach to Diabetes Care on A1C at a Community Health Center When Social Determinants of Health May Be a Barrier

(10-081) Impact of Pharmacist-run Ambulatory Care Clinic Post-discharge Visits on Congestive Heart Failure Readmission Rates

(10-176) Impact of Pharmacist Integration into the Denosumab Infusion Services Workflow

(10-187) A Retrospective Study of Obesity and Overweight Treatment and Outcomes in Primary Care

(10-190) Evaluating the Impact of Pharmacist Management of Osteoporosis in the Ambulatory Care Setting

(10-192) Retrospective Study on the Effectiveness of an Institution Specific Patient Risk Stratification Tool for Scheduling of Medicare Annual Wellness Visits with a Pharmacist

(10-199) Percent change in weight after three months of medical weight management in adult patients by primary care provider versus co-managed by a clinical pharmacist.

(10-204) Evaluation of the Role of a Pharmacist in the Management of Gestational Hypertension in an Obstetrics and Gynecology Clinic

(10-208) The Effect of Pharmacist Interventions on Chronic Kidney Disease in an Ambulatory Care Setting

(10-211) Overview of Pharmacist Diabetes Outcomes in the Primary Care Setting

(10-212) A Review of Guideline Directed Medication Therapy Adherence for Patients with Asthma

(10-214) Evaluation of Ambulatory Care Proton Pump Inhibitor Use

(10-219) Culturally Tailored, Pharmacist-Led Diabetes Education Intervention for Uninsured Hispanic Patients: Evaluation of Diabetes Knowledge Enhancement and A1c Improvement.

(10-228) Satisfaction Toward Virtual Pharmacy-led Clinic in Renal Transplant Recipients: A Cross-Sectional Study

(10-245) Implementation of a Validated Screening Tool (TAPS) to Improve Screening Rates of Substance Use Disorders in a Family Practice Clinic

(10-254) Pharmacist Impact on 30-day Hospital Encounters in Patients with Diabetes Managed in a Transitional Care Clinic

(10-255) The Impact of Clinical Pharmacist Intervention on the Rates of Gestational Diabetes Complications

(10-261) Efficacy of Tirzepatide on Weight Loss in Adult Patients of Lawrence Memorial Hospital (LMH) Health Primary Care Clinics

(10-291) Evaluating the clinical and financial impacts of integrating a clinical pharmacy team in an ambulatory endocrinology clinic

(10-327) Evaluation of Patient Satisfaction with Anti-CD20 B-cell Depletion Therapy in Multiple Sclerosis

(10-359) Assessing Prescribing Patterns in the Management of Diabetic Peripheral Neuropathy

(10-369) The Influence of a Pharmacist Driven Protocol on Hemoglobin A1C in Overbasalized Patients with Type 2 Diabetes at a Federally Qualified Health Care Organization

(10-370) The evaluation of proper inhaler use with the implementation of In-Check Dial in the management of COPD and asthma at a Federally Qualified Health Center

(10-374) Design and Implementation of a Direct Oral Anticoagulant To-Go Program for Venous Thromboembolism in a Community Hospital

(10-383) Real-World Visual and Anatomical Outcomes of Faricimab Use in Ophthalmology Patients with Neovascular Age-Related Macular Degeneration and/or Diabetic Macular Edema

(10-384) Evaluation of the impact of pharmacist-led medication reconciliations post-hospital discharge on readmissions in a select high-risk population

(10-401) Assessing Pharmacist’s Role in Direct Oral Anticoagulant Management in the Ambulatory Care Setting

(10-406) Impact of Pharmacist-Led Medication Reconciliation on HIV Patient Outcomes in an Interprofessional Outpatient HIV Clinic

(10-416) Evaluating the Impact of a Transition of Care Service in Clinical Outcomes of Patients with Diabetes

(10-426) Impact of Semaglutide versus Dulaglutide on Weight in Patients with Diabetes and Obesity at a Federally Qualified Health Center within a Predominantly Hispanic Community

(10-427) Comparison of Metabolic Profiles of Low-Dose Quetiapine versus Mirtazapine for Individuals with Insomnia at a Federally Qualified Health Center

(10-432) Impact of the Addition of Virtual Care in Ambulatory Care Clinical Pharmacy Diabetes Clinics on HgbA1c

(10-450) Impact of Retail Pharmacy Meds to Beds with Ambulatory Pharmacotherapy Clinic Services on 30 Day Readmission Rates at a Community Hospital

(11-003) Optimizing Healthcare: Implementation of a Pharmacist-Driven Transitions of Care Pilot Program

(11-021) Pharmacist Led Management of Glucagon-Like Peptide 1 Receptor Agonists

(11-029) ​​The Impact of an Ambulatory Care Elective: Evaluating Student’s Perceptions and Entry-Level Competencies Post-Ambulatory Care APPE​

(11-075) Osteoporosis Treatment and the Use of a Collaborative Practice Agreement: Does Pharmacist Clinician Intervention Lead to Better Patient Outcomes?

(11-076) Evaluation of Pharmacist-led GLP-1 Utilization and Management of Type 2 Diabetic Patients Compared to Primary Care

(11-082) Effects of Chart Review and Pharmacist Interventions on Diabetes Gap Scores in the Rural Ambulatory Care Setting

(11-096) Review of Direct Oral Anticoagulants Dosing and Associated Indications at a Central Minnesota Health System

(11-100) Assessment of the Efficacy of Semaglutide and Tirzepatide in the Management of Weight Loss in a Rural Internal Medicine Ambulatory Clinic in Mississippi

(11-124) Patient Perceptions Regarding Shortages of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus

(11-137) Impact of a Pharmacy Technician in a Pharmacist-led Diabetes Clinic

(11-146) Impact on Prescribing Rates of SGLT2-Inhibitors Through Pharmacist Interventions in Patients with Diabetes and Heart Failure

(11-171) Evaluation of the safe transition between methotrexate formulations in a pharmacist-supported rheumatology clinic

(11-176) Suboxone Clinic Patient Perceptions on Clinical Pharmacist Intervention at a Federally Qualified Health Center

(11-177) Impact of Pharmacy-led Asthma Clinic on Asthma Control in the Primary Care Setting

(11-187) Evaluating the Impact of Continuous Glucose Monitoring on Patients with Malignancies at Risk of Steroid Induced Hyperglycemia

(11-227) Identifying Treatment Gaps and Disparities in Patients with Non-Valvular Atrial Fibrillation Within a Community Hospital Ambulatory Setting: Opportunity to Improve Ambulatory Anticoagulation Practices

(11-261) Appropriateness of statin therapy as primary prevention in elderly patients

(11-272) Evaluation of patients prescribed warfarin who can be converted to a DOAC in a medically underserved, family medicine clinic

(11-296) Optimization of Pharmacotherapy to Improve Renal Outcomes in Patients with Diabetes and Chronic Kidney Disease Receiving Care at a Community Clinic

(11-312) Examining primary care prescribing patterns of inhaled asthma reliever therapies among adult patients at a federally qualified health center

(11-342) Effect of Glucose-Dependent Insulinotropic Polypeptide (GIP)/Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist and GLP-1 Receptor Agonists on Renal Outcomes in Patients with Type 2 Diabetes Mellitus

(11-399) Evaluation of Patients Discharged From Pharmacist-Led Collaborative Drug Therapy Management (CDTM) Primary Care Clinic

(11-410) Optimizing Guideline Directed Therapy for Asthma Management and Reduce Asthma Inhaler Polypharmacy

(11-415) The Effect of Glucagon-like Peptide-1 Receptor Agonists and Mounjaro on Patients' Insulin Requirements

(11-421) Evaluation of the Impact of a Clinical Pharmacist-led Diabetes Management Program at an Ambulatory Care Clinic

(11-426) Assessing Respiratory Syncytial Virus (RSV) Vaccine Interest in an Urban Geriatrics Clinic

(11-447) Impact of Ambulatory Care Pharmacists on Heart Failure Patients in an Outpatient Setting

(11-454) Evaluating the Frequency of Co-prescribing of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Glucagon Like Peptide-1 (GLP-1) Agonists Among Patients with Type 2 Diabetes Mellitus

(12-003) Evaluation of the Impact on Weight Loss with Glucagon-like Peptide-1 Receptor Agonists or Glucose-dependent Insulinotropic Polypeptide/Glucagon-like Peptide-1 Receptor Agonist at Doses Not Indicated for Obesity

(12-006) Medication Use Evaluation of Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors in Patients Without Diabetes

(12-027) Impact of Pharmacist Targeted Interventions in the Management of Chronic Kidney Disease in Patients with Hypertension

(12-028) Appropriate use of GLP1-RAs, SGLT2 Inhibitors, and Statins in Patients with Managed Medicaid Insurance

(12-046) Evaluation of Prescribing and Monitoring Practices for Direct Oral Anticoagulants By Providers and Outpatient Clinics

(12-052) Assessment of Pharmacist Sustainability and Qualitative Impact in a Rural Health Clinic

(12-059) Comparison of Patient Monitoring and Follow-up on Direct Oral Anticoagulant Therapy Following Pharmacist Intervention versus Standard Care

(12-064) Assessing Appropriate Dosing of Apixaban and Rivaroxaban for Extended Treatment of VTE: A Retrospective Chart Review

(12-065) Evaluation of patients on warfarin transitioned to direct oral anticoagulants enrolled in an Ambulatory Pharmacy Medication Management Care Clinic

(12-074) Evaluation of Compliance to Retinal Toxicity Monitoring in Patients Receiving Hydroxychloroquine

(12-079) Comparison of HFrEF GDMT Prescribing with Pharmacist Intervention versus Usual Care

(12-085) Inclisiran Efficacy and Financial Impact for Outpatient Use

(12-090) Evaluation of Compliance to Select Specialty Medication Lab Monitoring in the Ambulatory Care Setting

(12-098) Examining the Impact of a Pharmacist-Managed Diabetes Program in an Internal Medicine Clinic: A Retrospective Matched Cohort Study

(12-104) Evaluation of Continuous Glucose Monitoring (CGM) Managed by Pharmacists Compared to Primary Care Providers (PCP): Impact on Hemoglobin A1c% (HgA1c%)

(12-106) Effects of tirzepatide on HbA1c and body weight after switching from semeglutide or dulaglutide

(12-127) Introduction of an ambulatory care pharmacist team in a pediatric asthma clinic

(12-138) Weight Loss Outcomes Associated with Semaglutide Treatment for Patients with Overweight or Obesity in a Rural Ambulatory Clinic

(12-141) COPD Exacerbation Rate Between Dual Combination Inhaler Therapy Compared to Triple Combination Therapy

(12-148) Development of a Nicotine Cessation Clinic Within a Community Hospital in Rural Ohio

(12-151) Continuous Glucose Monitoring in the Primary Care Setting and the Risk of Diabetic Emergencies

(12-155) Effects of a pharmacist-led deprescribing initiative in a family medicine residency clinic

(12-160) Characteristics of adult patients with diabetes admitted to an academic medical center for hypoglycemia events

(12-166) Impact of Continuous Glucose Monitoring on Pharmacist Management of Type 2 Diabetes Mellitus

(12-172) Impact of a Pharmacist-Led Employee Wellness Hypertension Program Utilizing Remote Monitoring Devices

(12-173) Implementation of an Pharmacist-Led Employer-Based Weight Management Program in a Rural, Ambulatory Care Setting

(12-183) Evaluating the Effect on Total Daily Insulin Dose in Adult Patients with Type 1 Diabetes Managed with Metformin and/or GLP-1 or GLP-1/GIP Receptor Agonists

(12-187) Effect of Continuous Glucose Monitoring on Glycemic Control for Patients with Type 2 Diabetes Enrolled in an Employee Wellness Program

(12-194) Retrospective review of asthma control following initiation of inhaler therapy in outpatients with mild asthma

(12-195) Comparing Weight Loss Benefit of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide 1 Agonists in Patients with Type 2 Diabetes

(12-196) Comparing Glycemic Impact of Mounjaro (tirzepatide) vs. Ozempic (semaglutide) vs. Trulicity (dulaglutide)

(12-197) Pharmacist Led Interventions Through Post Discharge Ambulatory Pharmacy Program; The Effectiveness, Outcomes, and Impact of Optimized Type 2 Diabetes Management Reflected by Reduced HbA1c Values

(12-208) Project DAWN Fentanyl Test Strip Distribution, NaloxBox Implementation, and Expansion on Naloxone Distribution throughout University Hospitals

(12-209) UH Meds Culture Callback Expedited Partner Therapy

(12-211) Role of the Pharmacist in Comprehensive Management of Heart Failure as an Integral Member of the Interdisciplinary Team

(12-219) Compare the Impact of Tirzepatide on Type 2 Diabetes Mellitus Related Outcomes in a Comprehensive Medication Management Program

(12-229) Impact of Social Determinants of Health Barriers on the Initiation and Utilization of Continuous Glucose Monitors (CGMs) for Adults with Type 2 Diabetes.

(12-237) Optimizing Asthma Control by Switching to SMART Therapy in Patients with Uncontrolled Asthma

(12-238) Modifying Pharmacist-Led Diabetes Case Management Care Model to Enhance Patient Identification and Expand Care Capacity within a Managed Care Delivery System

(12-249) Implementation of routine CYP2C19 pharmacogenetic testing to guide antiplatelet therapy post-percutaneous coronary intervention

(12-254) Impact of Pharmacist-led Care on Type 2 Diabetes Mellitus Outcomes in a Rural, Primary Care Setting

(12-256) Outcomes of a Clinical Pharmacist in a Rural Clinic

(12-259) Evaluation of Statin Use and Achievement of LDL Targets among Adult Patients with Diabetes at a FQHC

(12-262) Percentage of Patients with Type II Diabetes Mellitus and Cardiovascular Disease Prescribed a GLP-1 Agonist or SGLT2 Inhibitor with Proven Cardiovascular Benefit

(12-264) Evaluation of the Management of Direct Oral Anticoagulants with the Concomitant Use of Nirmatrelvir/Ritonavir for Mild-Moderate COVID-19 Infections Within Allegheny Health Network (AHN)

(12-283) Evaluation of Laboratory Monitoring Following Initiation of a Sodium-Glucose Cotransporter-2 Inhibitor

(12-284) Evaluation of benzodiazepine use in patients without a maintenance medication for the treatment of anxiety in the Geisinger outpatient setting

(12-286) Evaluation of Patient’s Completion of the 2-dose Hepatitis B Vaccination Series Compared to the 3-dose Series

(12-287) Evaluation of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor (PCSK9i) Prescribing Practices for Patients with Clinical Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Low-Density Lipoprotein (LDL)

(12-308) Treatment Persistence of Off-label Biologic Disease Modifying Antirheumatic Drug Dosing Schedules for Patients with Spondyloarthritis Conditions

(12-344) Frequency of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonist concomitant use in a rural community health-system

(12-349) Evaluation of clinical outcomes of every 8-week versus every 6- and every 4-week Stelara dosing

(12-357) Evaluation of Pharmacist Impact on 30-Day Readmission Rates in a Multidisciplinary Family Medicine Transitions of Care Clinic

(12-361) Medication Use Evaluation of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss

(12-399) Review of Sacubitril/Valsartan Utilization in Patients with Heart Failure in a Pharmacist Led Ambulatory Clinic

(12-400) Evaluating Injectable Semaglutide Use and Alternative Therapies Following Price Increase and Backorders in a Pharmacist-led 340B Outpatient Clinic

(12-403) Effect of Remote Patient Monitoring (RPM) on Glucose Control in Patients Enrolled in a Diabetes Management Program

(12-419) Evaluation of Subcutaneous Furosemide in an Outpatient Advanced Heart Failure Clinic

(12-427) Direct oral anticoagulant appropriateness in a geriatric primary care clinic

(13-001) Assessment of Sex Disparities in Lipid Lowering Therapy Among Patients with Established Clinical ASCVD

(13-009) Evaluation of patient compliance with initial and second prescription fills for newly started antiplatelet agents post MI

(13-010) Impact of Pharmacist driven Preapproval Process for Parenteral Pulmonary Arterial Hypertension Therapies on Length of Stay

(13-016) Determining the Need for a Pharmacist Led Congestive Heart Failure Titration Clinic by Evaluating Current Prescribing Trends

(13-026) Initiating Antidepressant Therapy: Examining Resident Physician Prescribing Practices and Attitudes Towards Antidepressant Medications in Primary Care

(13-082) Assessment of Inhaled Corticosteroid Prescribing Patterns in Patients with Chronic Obstructive Lung Disease

(13-106) Evaluation of Lipid Management in Very High Risk Patients of an Outpatient Cardiology Practice

(13-110) Impact of pharmacist involvement in the transitions of care process at an academic medical center

(13-125) Evaluation of Diabetes Care with Pharmacist Management

(13-130) Evaluation of Remote Pharmacist Intervention on Type 2 Diabetes HbA1c Reduction in an Accountable Care Organization

(13-168) Patient Perspectives on Use of American Diabetes Association Guideline-Compliant Language Recommendations Among People with Diabetes at Federally Qualified Health Centers

(13-169) Continuous Glucose Monitoring (CGM) Based Glycemic Control Among Underserved Populations with Type 2 Diabetes at a Federally Qualified Health Center (FQHC)

(13-192) Expansion of Diabetes Clinical Pharmacy Telemedicine Services at a Large Academic Health System

(13-221) Implementation and Integration of a Pharmacist-Driven Pharmacogenomics Service In a Rural Behavioral Health Clinic

(13-253) Intermountain Medication Assistance Program and its Benefit on Medication Adherence

(13-261) Retrospective Review of Clinical Outcomes when Comparing Tirzepatide to Dulaglutide in Adult Type 2 Diabetes Mellitus at Intermountain Health

(13-296) Medication Use of Insulin in the Transitions of Care Setting

(13-299) Evaluating the Effect of Prescribing GLP-1 Receptor Agonists Alongside DPP-4 Inhibitors for Treatment of Type 2 Diabetes Mellitus

(13-306) Continuous Glucose Monitoring Devices To Help Aid Patients With Type 2 Diabetes Increase Physical Activity

(13-310) Appropriateness of Empiric Antibiotic Therapy for Treatment of Uncomplicated Cystitis at a Charitable Medical Clinic

(13-324) Assessing the Role of Pharmacist Intervention in Patients Initiating New Anticoagulation Therapy

(13-337) Creation of a Pharmacist-Run Outpatient Antipsychotic Injection Service

(13-346) Impact of a Collaborative Transitions of Care Clinic on Readmission Rates

(13-347) Clinical pharmacists' impact on population health outcomes in primary care

(13-352) Assessing the Impact of A Pharmacist-Led Multiple Sclerosis Service

(13-363) Optimization of laboratory draw workflow in a Pharmacist-Led Osteoporosis Pharmaceutical Care Clinic

(13-364) Pharmacist-Driven Asthma Management Service in the Ambulatory Care Setting

(13-384) Standardizing Virginia Mason Franciscan Health Patient Medication Assistance Program Protocol

(13-386) Predictors, disparities, and prescription patterns of kidney protective medications among patients with diabetes and chronic kidney disease

(13-409) A Review of the Effects Patient Financial Assistance has on Glycemic Control in Patients with Type I and Type II Diabetes Mellitus

(13-411) Assessment of Glycemic Control in Patients with Combined Continuous Glucose Monitoring and Pharmacist Intervention

(13-423) Impact of Glucagon-like Peptide 1 Receptor Agonists (GLP-1) Use on Patient Outcomes Throughout a Statewide Healthcare System

(13-437) Impact of a Pharmacist Led Comprehensive Medication Management Review in Patients with Type 2 Diabetes in a Rural Health Care Setting

(13-439) Incorporation of a Clinical Pharmacist into Care of Patients with Cystic Fibrosis in a Rural Health Care Setting

(13-441) GLP-1 RA’s... Are you getting a bang for your buck?

(13-445) Establishing a Pharmacist-Assisted Buprenorphine-Naloxone Induction and Maintenance Service

(13-446) The Impact of Pharmacogenomic Testing on PHQ-9 Scores in Patients with Depression

(13-453) Clinical pharmacist implementation into UnityPoint Health – Meriter maternal fetal medicine (MFM) clinic workflow

(1-005) Coronary Endoprothesis: State of Play and Prescription Critical Analysis at a University Hospital

(1-045) The impact of implementing a venous thromboembolism prophylaxis protocol at a tribal health care inpatient facility

(1-066) Evaluation of Empagliflozin Initiation During Hospitalization for Heart Failure Patients at a Federally Affiliated Institution

(1-070) Anticoagulation Stewardship at VA Loma Linda: Identifying and Intervening Untreated Atrial Fibrillation/Flutter Veterans where Anticoagulation Therapy is Indicated

(1-098) Expansion & Optimization of a Pharmacy-Run Inpatient Anticoagulation Service at James A. Haley Veterans’ Hospital

(1-106) Impact of Pharmacy-led Addition of SGLT2i in Patients Treated for HFrEF via the Population Management Tool in Accordance with Guideline Directed Medical Therapy

(1-117) Evaluation of Clinical Pharmacist Practitioner Interventions in a Pharmacist-Run Heart Failure Shared Medical Appointment

(1-121) Evaluating Current Periprocedural/Perioperative Anticoagulation Management for Direct Oral Anticoagulants (DOAC) and Warfarin

(1-123) Comparison of sotalol and dofetilide for successful initiation and continuation in atrial fibrillation patients

(1-127) Stroke Prevention in Atrial Fibrillation/Flutter: Targeting the Untreated While Prioritizing Disparities

(1-132) Impact of Provider Location on Oral Anticoagulation Prescribing Patterns in Veterans with Atrial Fibrillation or Flutter

(1-133) Evaluation of Predetermined Health Disparity Impact on Patients with Atrial Fibrillation or Flutter Without Stroke Prophylaxis at a Veteran Affairs Medical Center

(1-135) Aspirin Deprescribing or Proton Pump Inhibitor Prescribing in Patients on Concomitant Aspirin and Oral Anticoagulation Therapy

(1-153) Retrospective analysis of direct oral anticoagulant hold recommendations for gastrointestinal procedures by an outpatient anticoagulation clinic

(1-169) Impact of Pharmacist Education on Veterans Hospitalized with Hypertension

(1-175) Evaluating Bleeding Events in the Elderly Veteran Population Receiving FDA-Approved Doses of Apixaban or Rivaroxaban

(1-177) Evaluation of a Pharmacist-Led Intervention to Deprescribe Nonsteroidal Anti-Inflammatory Drugs in Patients with Heart Failure

(1-185) Early Optimization of Guideline-Directed Medical Therapy in Veterans with Heart Failure

(1-189) Impact of Pharmacist Intervention on IV Iron Usage Among Patients with Heart Failure at the Minneapolis Veterans Affairs Health Care System (MVAHCS)

(1-194) Enhancing Primary Care Prescribing of PCSK9 Inhibitors for Secondary Prevention of ASCVD in High Risk Patients at the Minneapolis Veterans Affairs Health Care System (MVAHCS)

(1-210) Evaluation of Aspirin Use for Primary Prevention in Veterans on Chronic Oral Anticoagulation

(1-211) Evaluation of Bleeding Risk for Veterans on Warfarin

(1-220) Stoke Prevention in Atrial Fibrillation/Flutter - Targeting the Untreated with a Focus on Health Disparities - At VA Sierra Nevada Medical Center

(1-242) Evaluation of Tafamidis Treatment in Veterans Diagnosed with Transthyretin Amyloid Cardiomyopathy

(1-252) Identifying racial disparities in the management of heart failure with reduced ejection fraction

(1-254) Ensuring Guideline-Directed Medical Therapy in patients with Heart Failure with Reduced Ejection Fraction through Pharmacist Consultation in the Primary Care Setting

(1-265) Stroke Prevention in Atrial Fibrillation/Flutter: Targeting the Untreated While Prioritizing Health Disparities at the Salisbury VA Health Care System

(1-280) Pharmacist Evaluation and Discontinuation of Inappropriate Aspirin Therapy in Elderly Patients Prescribed Direct Oral Anticoagulants

(1-284) Describe the Management of Heart Failure with Reduced Ejection Fraction Post Hospitalization at the Oklahoma City Veterans Health Care System

(1-292) Magnesium in Atrial Fibrillation: a Retrospective Review Evaluating Safety and Efficacy of Intravenous Magnesium for Attainment of Rate and Rhythm Control

(1-293) Evaluating the impact of interventions for warfarin-treated Veterans with low time-in-therapeutic range (TTR) in a pharmacist-led anticoagulation clinic within a Veteran Affairs Health Care System

(1-302) Implementation of Pharmacogenomic Testing to Evaluate the Efficacy of Clopidogrel in Patients Post Percutaneous Coronary Intervention (PCI)

(1-311) To Prescribe or Deprescribe: Antiplatelet Discontinuation versus Proton Pump Inhibitor (PPI) Addition in Veterans with Combined Antithrombotic Therapy

(1-321) Utilization of Population Health Dashboards to Improve Cardiology Medication Monitoring in a Rural Veterans Affairs Health Care System

(1-322) Outcomes of an Initiative to Decrease Non-steroidal Anti-inflammatory Use Among Outpatient Veterans Taking Direct Oral Anticoagulants

(1-325) Pharmacist-Led Initiative to Improve Glycemic Control Therapies in Veterans

(1-328) Impact of Obesity on Heart Failure Hospitalization in Veterans on Sacubitril/Valsartan

(1-330) Impact of Race on Heart Failure Admissions in Veterans on Sacubitril/Valsartan

(1-343) Safety Evaluation of Direct Oral Anticoagulants vs. Warfarin in Veterans with Cirrhosis

(1-366) Retrospective analysis of angiotensin receptor-neprilysin inhibitor compared to angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers and effect on hospitalizations in patients with heart failure

(2-060) Age at First Cannabis Use as a Predictor of Adult Heart Disease

(2-066) Targeted Medication Discharge Counseling by Pharmacists: Quality Improvement Project and Standardization of Procedures

(2-073) Population health pharmacotherapy optimization of sacubitril/valsartan for patients with heart failure reduced ejection fraction

(2-117) Racial/Ethnic Disparities in the Baseline Cardiovascular Risks in Patients Who Underwent Percutaneous Coronary Intervention (PCI)

(2-129) Factors Influencing Tolerability of Angiotensin Receptor/Neprilysin Inhibitor for Heart Failure with Reduced Ejection Fraction (HFrEF) in the Inpatient Setting

(2-133) Sex Differences in the Cost-related Medication Adherence in Patients with HTN, CVD and HF: An All of Us Study

(2-145) Apixaban for Atrial Fibrillation with or without Aspirin After Transcatheter Aortic Valve Replacement

(2-155) Impact of Fixed-Dose Compared to Weight-Based 4-Factor Prothrombin Complex Concentrate for Factor Xa Inhibitor Reversal

(2-180) Sodium-Glucose Co-Transporter-2 Inhibitor Prescribing Patterns in Heart Failure with Reduced Ejection Fraction Patients Admitted to a Major Academic Medical Center

(2-191) Incidence of Venous Thromboembolism in Trauma Patients before and after Institution of a Venous Thromboembolisms Prophylaxis Protocol

(2-204) Retrospective evaluation of an established pharmacy dosing protocol of enoxaparin in obesity at a community hospital

(2-218) Comparing Activated Partial Thromboplastin Time versus Anti-Factor Xa Monitoring for Intravenous Heparin Infusions via Nursing-Driven Network Protocols

(2-219) Analysis of Nicardipine Infusion Titration Approaches in an Acute Care Setting

(2-228) Evaluating Proper Amiodarone Loading during Admission and Discharge in Patients across a Health System

(2-266) Evaluating the role of sodium-glucose cotransporter-2 inhibitors in the management of acute decompensated heart failure

(2-274) Investigating the Place of Sodium-Glucose Cotransporter-2 Inhibitors and Dual Sodium-Glucose Cotransporter-1 and -2 Inhibitors in Heart Failure Therapy: A Systematic Review of the Literature

(2-303) Blood Product Sparing Effect of Preoperative Vitamin K Administration in Cardiac Surgery

(2-304) Assessing the Efficacy and Safety of Ibutilide for Pharmacologic Cardioversion to Normal Sinus Rhythm

(2-319) Evaluation of Prophylactic Enoxaparin Use in Extreme Body Weights

(2-325) Assessment of Provider Knowledge and Therapeutic Approaches for Reducing Stroke Risk in Patients with Nonvalvular Atrial Fibrillation

(2-329) Demographic Reporting and Subgroup Analysis: A Study on Premarketing Trials of SGLT2 Inhibitors

(2-343) Real-World Analysis of Inpatient Guideline-Directed Medical Therapy Management for Chronic Heart Failure

(2-378) Evaluation of a Pulmonary Embolism in a 21-year-old African American Male with Tetralogy of Fallot and Secondary Complications

(2-384) Impact of Insurance Status on LDL-C Treatment Threshold Achievement in Patients with Atherosclerotic Cardiovascular Disease

(3-014) Evaluation of the Effectiveness and Need for Pharmacist Intervention of Direct Oral Anticoagulants

(3-058) Evaluation of Heparin Infusion Dose Adjustments Using Institutional Acute Coronary Syndrome and Medical Heparin Infusion Protocols

(3-107) Prevalence of ICU patients with risk of drug-induced QT prolongation in Saudi Arabia

(3-111) Medication Use Evaluation of Apixaban and Rivaroxaban Dosing Practices in Atrial Fibrillation at a Large, Single-Center Institution

(3-145) Evaluation of excessive INR elevation during warfarin therapy in anticoagulation service

(3-151) Evaluation of Intravenous Iron Replacement in Patients with Iron Deficiency and Acute Decompensated Heart Failure

(3-153) Therapeutic Enoxaparin Dosing in the Inpatient Obese Population

(3-187) Evaluation of a Pharmacy-Driven Enoxaparin Protocol in Obese Patients

(3-193) Assessing the Readability of Pulmonary Hypertension Drug Product Patient Package Inserts

(3-199) A Retrospective Medication Use Evaluation Regarding a Community Based Hospital’s Heparin Protocols

(3-206) Barriers to Guideline-Directed Medical Therapy in Patients with Heart Failure with Reduced Ejection Fraction at Hospital Discharge

(3-226) Investigation of the Anticoagulant Activity of Cyclic Sulfated Glycosaminoglycan Mimetics

(3-233) Evaluation of a No Bolus Heparin Drip Protocol vs Standard Bolus Heparin Protocol in the Treatment of VTE

(3-237) Direct Oral Anticoagulants With or Without Antiplatelet Agents Versus Antiplatelet Agents Alone in Patients With Lower Extremity Peripheral Arterial Disease Following Revascularization

(3-239) Direct Oral Anticoagulants versus Warfarin in Patients with Isolated Heparin-induced Thrombocytopenia or Heparin-induced Thrombocytopenia with Thrombosis

(3-248) Comparison of Bivalirudin to Heparin in Pediatric Patients on Extracorporeal Membrane Oxygenation (ECMO)

(3-250) Prevalence of Mortality Benefit Beta Blockers Prescribed at Discharge Following Myocardial Infarction in Patients with Heart Failure with Reduced Ejection Fraction

(3-266) Assessing Adherence to IV Iron Therapy Recommendations in Patients with Heart Failure with Reduced Ejection Fraction and Iron Deficiency Anemia

(3-268) ALDH2 Deficiency and Nitroglycerin (NTG) Efficacy: Focus on Asian American Acute Angina Patients

(3-272) Potential drug interactions of direct oral anticoagulants with anticancer drugs in hospitalized patients

(3-305) Appraisal of Cost-Free Heart Failure Applications Available for Patient Self-Monitoring.

(3-327) Evaluation of Patient Characteristics and Patient-Physician Interaction Scores in Older Adults with Atrial Fibrillation (AF): The SAGE-AF study

(3-339) Aspirin De-escalation in Patients with Stable Coronary Artery Disease and Atrial Fibrillation on a Direct Oral Anticoagulant: a Retrospective Review

(3-345) Analysis of Pharmacist Interventions on Prophylactic Enoxaparin to Support Proposal of an Automatic Dosing Policy

(3-350) Analyzing the Use of Direct-Acting Oral Anticoagulant in Fragile Population with Venous Thromboembolism and Atrial Fibrillation

(3-368) Reduction in the Risk for Hospitalizations Associated with Beta-blockers in Self-identified Black and White Patients with HFrEF

(4-010) Applying Implementation Science to a Formalized Proposal of Optimizing Transitions of Care as a Part of Anticoagulation Stewardship

(4-011) Pharmacist-Led Care in Collaboration with a Cardiovascular Team to Improve the Management of Atherosclerotic Cardiovascular Disease Risk in Hospitalized Patients

(4-012) Evaluation of the Appropriate Use of Amiodarone for Atrial Fibrillation (AF) Prophylaxis in Post Coronary Artery Bypass Graft (CABG) Surgery Patients

(5-055) Assessment of Four-factor Prothrombin Complex Concentrate Use for the Reversal of Apixaban and Rivaroxaban in Intracranial Hemorrhage at an Academic Medical Center

(5-105) Retrospective Study on SGLT-2 Inhibitor Discontinuation Rates for Inpatient Initiation

(5-117) Evaluation of the Safety of Sodium-Glucose Cotransporter 2 Inhibitor Initiation in an Inpatient Post-Cardiothoracic Surgery Patient Population

(5-157) Retrospective Review of Prescribing Practices at Discharge for Patients with Type 2 Diabetes Admitted Due to an Atherosclerotic Cardiovascular Event

(5-158) Racial, Ethnic, and Socioeconomic Disparities in P2Y12 Inhibitor Prescribing Trends Following Percutaneous Coronary Intervention in Medicare Beneficiaries with Acute Coronary Syndrome

(5-181) Retrospective Evaluation of LDL Reduction with Inclisiran at a Private Cardiology Practice

(5-199) Outcomes Associated with the Prescription Use of Statins or Antiplatelets in Patients with Spectrums of Non-obstructive Coronary Artery Disease (NOCAD)

(5-205) Analyzing the indication of use with regards to rivaroxaban 2.5 mg twice daily dosing in an inpatient setting.

(5-227) Outcomes Associated with Inpatient Dapagliflozin Initiation in Patients with Heart Failure

(5-289) Evaluating Cardiologist's Knowledge of Pharmacogenomics

(5-307) Readmission Rates in Patients with Heart Failure with Reduced Ejection Fraction on Guideline-Directed Medical Therapy at Hospital Discharge

(6-043) Evaluating Anticoagulation and Hemostasis Management in a Community Hospital

(6-044) Evaluation of Bleeding Events Related to Direct Oral Anticoagulants at a Veteran Affairs Medical Center

(6-052) Evaluation of Full Versus Abbreviated Loading Durations of Apixaban and Rivaroxaban After Initial Parenteral Anticoagulation in the Treatment of Venous Thromboembolism

(6-059) Medication-use Evaluation of IV(Intravenous) Sotalol within an Academic Medical Center

(6-205) Evaluation of Fixed Dose 4F-PCC Reversal for Warfarin

(6-206) Comparison of Heparin Infusion Time-In-Range with Pharmacist Intervention Versus without Pharmacist Intervention

(6-216) Sodium-Glucose Cotransporter-2 Inhibitor Initiation in Patients Hospitalized for Heart Failure

(6-260) Safety Outcomes Associated with Rate-Controlling Medications to Manage Atrial Fibrillation in Patients with Heart Failure

(6-261) Outcomes Associated with Rate Control Strategies in Patients with Atrial Fibrillation and Heart Failure

(6-275) Assessing Appropriate Dual Antiplatelet Therapy (DAPT) Usage Among Participants in the Program of All-Inclusive Care for the Elderly (PACE-RI) of Rhode Island

(6-281) Do Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Differ in Their Effects on the Risk of Dementia in Systematic Reviews/Meta-Analyses of Hypertension Randomized Controlled Trials?

(6-297) Failure Was Not An Option: Implementation of Multidisciplinary Approach to Inpatient Heart Failure Education for Discharge

(6-318) Assessment of Practitioner Knowledge and Therapeutic Approaches for Reducing Stroke Risk in Patients with Nonvalvular Atrial Fibrillation

(6-325) Assessment of Weight Loss and Adverse Effects with Phentermine/Topiramate in Left Ventricular Assistance Device Patients

(7-013) 90-day Stability Investigation of Individually Repackaged Prasugrel Tablets

(7-133) Dapagliflozin in acute decompensated heart failure patients with reduced ejection fraction versus mildly reduced or preserved ejection fraction

(7-156) Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Impact on the Microbiome: Systematic Review

(7-176) Angiotensin Converting Enzyme Inhibitor Washout Period Prior to Angiotensin Receptor Neprilysin Inhibitor Initiation in the Inpatient Setting

(7-177) Assessing the safety and efficacy of enoxaparin and unfractionated heparin dosing regimens for venous thromboembolism prophylaxis in hospitalized morbidly obese patients: a systematic review

(7-180) Would’ve, Could’ve, Should’ve: Evaluation of guideline-directed medical therapy prescribing behavior in chronic heart failure upon discharge from a hospital readmission

(7-184) Identifying the gap in anticoagulation in Medicare Shared Savings Program patients with atrial fibrillation and stroke

(7-212) Evaluation of Direct Oral Anticoagulants Dosing for Treatment of Left Ventricular Thrombus

(7-213) Evaluation of Maximum Weight-Based Dosing Initiation Rate for Low Dose Heparin Protocol in Obesity

(7-230) Comparison of Extended Direct Oral Anticoagulant Treatment Strategies for Venous Thromboembolism

(7-231) Who Are We Bridging? Description and Outcomes of Anticoagulated Patients Receiving Injectable Bridging Therapy

(7-232) Evaluation of Hyponatremia Risk Among Geriatric Patients Exposed to Selective Serotonin Reuptake Inhibitors and Thiazide Diuretics

(7-245) Medication Use Evaluation of Amiodarone at a Large Academic Medical Center

(7-254) Efficacy of Fixed-Dose 4-Factor Prothrombin Complex Concentrate Versus INR and Weight Based Dosing for Warfarin Reversal

(7-299) Inpatient Anticoagulation Services at University of Washington Medical Center Montlake: Annual Audit of Compliance with Standards of Practice

(7-319) Assessing the Influence of Social Determinants of Health on Warfarin Patients' Time in Therapeutic Range

(7-334) Impact of estimated vs. measured weight on the time to therapeutic unfractionated heparin level in the treatment of venous thromboembolism

(7-337) Evaluation of Direct Oral Anticoagulants in the Treatment of Patients with LV Thrombus Caused by Non-ischemic Cardiomyopathy

(7-343) Evaluation of adult heparin dosing chart implementation at a community hospital

(7-344) Impact of metoprolol succinate adjustment on the occurrence of arrhythmias in patients with acute decompensated heart failure exacerbation

(7-348) Evaluating Transitions of Care for Patients Newly Started on Warfarin within an Academic Medical Center System

(7-350) Evaluation of Prescribing, Dosing, and Monitoring of Intravenous Heparin at a Community Hospital

(7-356) Evaluation of reduced alteplase dosing for catheter declotting at an academic medical center

(7-359) Evaluation of Time to First Bleed in Patients with HeartMate 3 Left Ventricular Assist Device on Aspirin

(7-379) Antiplatelet and Gastrointestinal Prophylaxis Interventions in Veterans with Stable Coronary Artery Disease and Concurrent Anticoagulant Use

(7-385) Pharmacist-Driven Warfarin to Direct Oral Anticoagulant Transition

(7-387) Warfarin to Direct Oral Acting Anticoagulant (DOAC) Conversion and Evaluation

(8-010) Evaluation of Direct Oral Anticoagulant Use in the Management of Heparin-Induced Thrombocytopenia

(8-011) Learnings from Solutions Used to Inappropriate Direct Acting Oral Anticoagulant (DOAC) Prescribing

(9-009) The Appropriateness of Unfractionated Heparin Titrations Using a Heparin Infusion Protocol at a Community Hospital

(9-017) Evaluation of Pharmacist-Driven Nursing Protocol Changes and Education in Heparin Infusion Management

(9-024) Evaluation of the safety and efficacy of activated prothrombin complex concentrate for the reversal of oral anticoagulant agents

(9-036) How does the Initial Loop Diuretic Dose in Acute Decompensated Heart Failure Affect Time to Decongestion?

(9-039) Evaluation of efficacy and safety outcomes between labetalol and hydralazine in acute blood pressure management

(9-054) Clinical Outcomes in Obese vs Non-Obese Patients on a Heparin Infusion: A Multicenter Academic Retrospective Review

(9-063) Evaluation of Systemic Heparin Infusion Management with Percutaneous Ventricular Assist Devices: A Comparison of Purge Fluids

(9-073) Deprescribing warfarin in favor of initiating a direct oral anticoagulant to improve medication therapy and streamline patient care in a Federally Qualified Health Center

(9-079) Comparison of Heparin versus Direct Thrombin Inhibitors for Venovenous Extracorporeal Membrane Oxygenation Anticoagulation

(9-103) Assessing the Efficacy and Safety of Heparin and Lovenox (Enoxaparin) in the Management of Acute Coronary Syndrome Patients at Desert Valley Hospital: A Retrospective Study

(9-115) Safety and Efficacy of 4-factor Prothrombin Complex Concentrate for the Reversal of Direct Oral Anticoagulants in Intracranial Hemorrhage

(9-121) Evaluation of Sodium-glucose Cotransporter-2 inhibitors on Euglycemic Diabetic Ketoacidosis in Patients Admitted to an Academic Medical Center

(9-151) Evaluation of Adherence to Guideline Directed Therapy for Patients with Recent Acute Coronary Syndrome, History of Myocardial Infarction, and Peripheral Artery Disease at Hospital Discharge

(9-152) Venous Thromboembolism Transitions of Care Health Outcomes and Projects Evaluation

(9-153) Anticoagulation Quality Assessment and Risk Evaluation in Patients with Nonvalvular Atrial Fibrillation (NVAF)

(9-172) Comparing Cardioembolic Stroke Risk and Bleed Risk Among Rivaroxaban, Apixaban, Warfarin, and No Anticoagulation in Patients with Atrial Fibrillation and Chronic Kidney Disease

(9-177) Evaluating the Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Thrombocytopenic Patients

(9-196) Enhancing Outcomes in Heart Failure Patients: Pharmacist-Led Medication Education and Its Impact on 30-Day Readmissions, Medication Knowledge, and Patient Satisfaction

(9-228) Comparison of Intravenous (IV) Cangrelor and IV Tirofiban on the Incidence of Bleeding When Used for a Peri-procedural Bridge Therapy Post Percutaneous Coronary Intervention (PCI)

(9-235) Evaluation of Lidocaine Infusion Utilization for Non-Pain Indications in the Absence of Real-Time Therapeutic Drug Monitoring in a Five-Hospital Health System

(9-238) Impact of Pharmacy-Led Lipid Optimization Workflow in the Transitions of Care Setting (LOW-TOC)

(9-251) Off-Label Prothrombin Complex Concentrate Utilization for Management of Life-threatening Bleeding due to Apixaban or Rivaroxaban at a Community Teaching Hospital

(9-256) Medication Use Evaluation of Inhaled Treprostinil for Patients Without the Propriety Nebulization Device within a Large Academic Medical Center

(9-257) Evaluation of Hydroxocobalamin for Vasoplegic Shock in Cardiac Surgery

(9-259) Evaluation of a “Home Anticoagulant Not Ordered” Alert in the Electronic Medical Record Across the Yale New Haven Health System

(9-261) Case Review of Elevated International Normalized Ratio (INR) Greater than Five in Hospitalized Inpatients on Warfarin Therapy Across Yale New Haven Health System

(9-263) Assessing the Use of Intravenous Procainamide in the Management of Cardiac Arrhythmias across a Five-hospital Health System

(9-280) Evaluation of the Safe Use of Ibutilide in a Multicenter Health System

(9-291) Comparison of the Rate of Ischemic Stroke in Elderly Patients with Atrial Fibrillation Who Are Taking an Anticoagulant

(9-294) Apixaban versus Warfarin for Treatment of Venous Thromboembolism in Patients With Severe Renal Impairment: A Multicenter Study

(9-319) Evaluation of Anticoagulation Therapy in Non-Valvular Atrial Fibrillation (NVAF) Patients Treated with Thrombolytic Agents for Ischemic Stroke

(9-322) Evaluation of Diuretic Dosing in the Emergency Department for the Management of Acute Decompensated Heart Failure in a Community Hospital

(9-328) Tolerability and Adverse Events Using Intravenous versus Oral Sotalol Initiations

(9-340) Assessment of Acetazolamide versus Metolazone in Acute Decompensated Heart Failure

(9-346) The Impact of Pharmacy Clinical Decision Support Tools on Secondary Stroke Prophylaxis in Patients with Atrial Fibrillation and Acute Ischemic Stroke

(9-363) Evaluating 30-Day Heart Failure Readmission Rates in Patients with HFrEF Initially Discharged on Guideline Directed Medical Therapy

(9-375) Amyloid Cardiomyopathy: Pharmacists Using Health Systemwide Data Analytics to Support Cardiologist Screening

(9-380) Comparison of Activated Partial Thromboplastin Time versus Anti-factor Xa in a Community Hospital

(9-383) Evaluation of Guideline Adherence in Patients on Multiple Antithrombotic Therapy and Use of Gastrointestinal Prophylaxis

(9-394) Evaluating Prescribing Trends and Patient Outcomes: A Medication Use Evaluation of Cangrelor

(9-406) Impact of a Pharmacist Intervention Scoring Tool on Heart Failure Patients' Clinical Outcomes

(9-413) Pharmacist-driven Inpatient Dapagliflozin Program: Assessing Appropriateness and Continuity of Care

(9-423) Evaluation of Potassium and Magnesium Replacement Utilizing a Cardiac Electrolyte Replacement Protocol with Higher Goal Parameters

(9-445) Assessing Warfarin Efficacy and Safety in an Outpatient Anticoagulation Clinic Associated with an Acute Care Hospital

(9-451) Optimizing Prevention of Hospital-Acquired Venous Thromboembolism (VTE): Retrospective Validation of a VTE Prophylaxis Clinical Decision Support Model

(9-460) High-Dose vs. Standard-Dose Subcutaneous Heparin for Venous Thromboembolism (VTE) Prophylaxis in Hospitalized Obese Patients

(9-461) Assessment of the Bleeding Rates with DOAC Use in Patients with Thrombocytopenia

(9-467) Evaluating the Compliance of Enoxaparin in Deep Vein Thrombosis (DVT) prophylaxis in hospitalized patients who refuse treatment.

(9-471) Evaluation of Andexanet Alfa for Appropriate Use in Major Bleeding Events

(10-010) Direct Oral Anticoagulants In Acute Kidney Injury and the Incidence of Major Bleeding

(10-026) Safety and effectiveness of heparinized versus bicarbonate-based Impella purge solutions with concomitant systemic anticoagulation

(10-036) Impact of a Pharmacist-Led Heart Failure Therapy Optimization Program on 30-day Hospital Readmission Rate in Patients with Reduced Ejection Fraction

(10-076) Apixaban versus Warfarin for Treatment of Venous Thromboembolism in Patients with Severe Renal Impairment: A Multicenter Study

(10-078) Frequency of thrombosis and bleeding in pediatric patients after palliative cardiac shunt or stent procedures with VerifyNow monitoring at a single center

(10-086) Evaluating Continuous Infusion Diltiazem Use in Patients with Atrial Fibrillation with Rapid Ventricular Rate

(10-089) Effects of Sodium Bicarbonate on 24-Hour Survival after Return of Spontaneous Circulation for In-Hospital Cardiac Arrest

(10-102) A Comparative Study of Different Lead-in Dosing Strategies Using Direct Oral Anticoagulants (DOACs) for the Treatment of VTE

(10-103) Comparison of Twice Daily Hydralazine with Isosorbide mononitrate daily or dinitrate Twice Daily Compared to Thrice Daily Hydralazine with Isosorbide dinitrate in Congestive Heart Failure

(10-120) Comparison of Factor Eight Inhibitor Bypassing Activity and Recombinant Coagulation Factor VIIa for Refractory Bleeding in Cardiothoracic Surgery Patients

(10-133) Evaluation of Periprocedural Management for Elective Procedures in Pharmacist-Managed Anticoagulation Clinics in a Multi-Hospital Health System

(10-149) Development and Implementation of a Heart Failure Guideline-directed Medical Therapy (GDMT) Scoring Tool to Improve Outcomes

(10-175) Impact of Pharmacist Intervention on the Prescribing Rate of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure with Reduced Ejection Fraction

(10-185) Evaluating Effectiveness of Anti-Factor Xa Assay Versus Activated Partial Thromboplastin Clotting Time (aPTT) Monitoring for Pharmacist-Managed Heparin Dosing

(10-195) Assessment of Low Fixed-Dose Protocol of Activated Human Prothrombin Complex Concentrate (FEIBA) for Reversal of Warfarin-Induced Life-Threatening Hemorrhages at Community Healthcare System

(10-205) Enhancing Heart Failure Care: Implementation of Clinical Pharmacy Services Within an Existing Heart Failure Clinic

(10-230) Exploring the Role of Antithrombotic Stewardship Program Led by Clinical Pharmacist in Optimizing Direct Oral Anticoagulants Prescribing in a Tertiary Care Hospital

(10-238) A Retrospective Study Investigating Solid Tumor Cancer Patients That Developed VTE Who Would Have Benefitted From Proactive Anticoagulation Initiation Using Their Khorana Risk Score.

(10-250) Evaluation of Pharmacist Driven Enoxaparin Anti-Xa Monitoring

(10-266) Implementation of a Pharmacist Managed Warfarin Protocol in a Community Hospital

(10-278) Rebound Hypertension after Prolonged Nicardipine Infusion

(10-283) Monitoring Effectiveness and Safety of Implementing Pharmacist Guided Heparin Management in Achieving Time to Therapeutic Anti-Xa Levels Versus Nursing Protocol per aPTT Levels

(10-286) Evaluation of Heart Failure Readmissions and Goal Directed Medical Therapy in a Rural Kentucky Hospital

(10-299) Impact of pharmacist-driven patient education on all-cause readmissions in patients with heart failure

(10-306) Evaluation of Guideline-Directed Medication Therapy at Discharge in Patients with Heart Failure with Reduced Ejection Fraction (HFrEF) in a Community Teaching Hospital

(10-310) Inpatient Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Administration During Admission for Heart Failure Exacerbation

(10-315) Comparing the Lilo-Le-Louet (3L) Score to the 4T Score in Predicting Heparin-Induced Thrombocytopenia (HIT) in Cardiothoracic Surgery Patients Receiving Cardiopulmonary Bypass

(10-317) Addition of Vitamin C Supplementation for the Prevention of Post-Operative Atrial Fibrillation Following Cardiothoracic Surgery

(10-366) Utilization of the Clinical Process Improvement Program Framework to Improve Quality of Inpatient Pharmacist Warfarin Management in A Community Hospital Setting.

(10-367) Optimization of pharmacist managed warfarin therapy in a community hospital using the Clinical Process Improvement Leadership Program

(10-387) Metoprolol versus Diltiazem: Management of Atrial Fibrillation with Rapid Ventricular Response in Patients with Heart Failure with Reduced Ejection Fraction in the Emergency Department

(10-404) Implementation of a Direct Oral Anticoagulant (DOAC) Stewardship program: A Quality Improvement Initiative

(10-425) Impact of inpatient empagliflozin initiation on post-discharge diuretic doses in patients with heart failure

(10-428) Implementation of a Clinical Practice Guideline for Venous Thromboembolism Prophylaxis in Trauma Patients at a Community Hospital

(10-431) Implementation of Strategies to Guide Management of QT Prolonging Medications

(10-434) Efficacy, Safety, and Appropriateness of Pharmacological Venous Thromboembolism Prophylaxis Practice in Non-Surgical Hospitalized Patients with Extreme Weight in a Community Teaching Hospital

(11-002) Apixaban versus Warfarin for Treatment of Venous Thromboembolism in Patients With Severe Renal Impairment: A Multicenter Study

(11-011) Intraoperative Glucose Management in Patients Undergoing Cardiac Surgery

(11-013) Characterizing Sodium-Glucose Cotransporter-2 Inhibitor Use in Heart Failure Patients at an Academic Medical Center

(11-017) Assessment of the Value of Anticoagulant Interventions Initiated by Pharmacists

(11-019) Evaluation of Efficacy and Safety of 4-Factor Prothrombin Complex Concentrate in the Reversal of Apixaban and Rivaroxaban Related Acute Bleed

(11-032) Efficacy of Inpatient Sodium-glucose Cotransporter-2 Inhibitor Initiation in Heart Failure

(11-036) Serum magnesium associated with atrial fibrillation rates in cardiothoracic surgery (CTS)

(11-038) Evaluation of half-dose prothrombin complex concentrate in Cardiac Surgery

(11-061) Comparison of Warfarin Management Between Primary Care Provider and Pharmacist-Led Anticoagulation Clinics Within a Primary Care Network

(11-066) Retrospective Review of Guideline Concordance with Perioperative Anticoagulation Practices

(11-071) Evaluation of Appropriate Use and Safety of SGLT2 Inhibitor Therapy in the Inpatient Setting

(11-106) Outcomes Associated with the Concurrent Use of Beta Blockers and Continuous Inotropic Infusions

(11-121) Use of Tenecteplase as an Alternative Thrombolytic Agent to Alteplase for Acute Ischemic Stroke

(11-145) Is Enoxaparin 30mg Twice Daily Enough? Retrospective Chart Review Comparing Rates of Venous Thromboembolisms at a Level One Community Hospital Trauma Center

(11-190) Evaluation of Provider-Led Inpatient Digoxin Dosing

(11-203) Characterization of Prescribing Habits Surrounding Sacubitril-Valsartan Dose Titration in Patients With Heart Failure

(11-206) Impact of an Enhanced Clinical Pharmacy Service on Medication Optimization in Hospitalized Patients With Heart Failure

(11-208) Difference Between Alteplase and Tenecteplase Time to Therapy Completion in Acute Ischemic Stroke

(11-215) Appropriate Renal Dose Adjustment for Apixaban in Patients with Nonvalvular Atrial Fibrillation

(11-222) Evaluation of Warfarin Patient Readmissions: A Retrospective Study

(11-224) Evaluation of Appropriate Usage of Four-Factor Prothrombin Complex Concentrate

(11-225) Evaluation of Efficacy of Standard Heparin Protocol in Obese Patients

(11-230) Evaluation of Prescribing Patterns of Apixaban and Rivaroxaban Initial Doses Post Parental Anticoagulation for the Treatment of Venous Thromboembolism

(11-262) Evaluating the Appropriate Use of Direct Oral Anticoagulants in the Ambulatory Care Setting

(11-266) Impacts of Sacubitril/valsartan vs Lisinopril on All-Cause Hospital Admissions

(11-286) Impact of Pharmacist-Led Intervention on Prescribing of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Hospitalized Patients with Heart Failure with Reduced Ejection Fraction (HFrEF)

(11-288) High-Dose Atorvastatin Loading in ST-Elevation Myocardial Infarction Patients Before Primary Percutaneous Coronary Intervention

(11-289) Prescribing practices at a community teaching hospital of anticoagulation for VTE prophylaxis after orthopedic surgery

(11-293) The Safety and Efficacy of Direct Oral Anticoagulants in Patients with Bioprosthetic Heart Valves

(11-309) Evaluation of the Effect of Inappropriate Apixaban Dosing Among Patients Admitted for Adverse Thrombotic or Bleeding Events

(11-316) Evaluation of Laboratory Monitoring Frequencies for Unfractionated Heparin Infusions

(11-343) Evaluation of Heparin Venous Thromboembolism Prophylaxis at a Large Academic Medical Center

(11-346) Effect of Optimizing Guideline-Directed Medical Therapy before Discharge on Heart Failure Readmission in Patients Hospitalized with Heart Failure with Reduced Ejection Fraction

(11-347) Evaluation of Initial Heparin Infusion Dose Maximums on Goal Anti-Xa Levels

(11-353) Comparison of tenecteplase versus alteplase in acute ischemic stroke: a retrospective, longitudinal cohort study to evaluate safety and establish non-inferiority

(11-368) Evaluation of Cangrelor Usage at Mount Sinai Health Systems (MSHS)

(11-374) Assessing Appropriateness of Enoxaparin Standard Treatment Dose in Obesity

(11-379) Assessing the Real World Use of Direct Oral Anticoagulants Versus Warfarin for the Treatment of Left Ventricular Thrombus

(11-389) Medication use evaluation of cangrelor at a large academic medical center

(11-400) Association between Obesity and Venous Thromboembolism (VTE) Incidence in Hospitalized Patients on Apixaban or Rivaroxaban.

(11-401) Effect of Dapagliflozin Initiation on Hospital Readmission Rates for Heart Failure with Reduced Ejection Fraction

(11-409) Evaluation of Apixaban Use for Venous Thromboembolism Prophylaxis in Post-Bariatric Surgery Patients at a Community Teaching Hospital

(11-420) Assessment of Guideline-Directed Medical Therapy (GDMT) for Heart Failure: Focus on 30-day Readmission for Patients Discharged on Dapagliflozin Following Heart Failure Admission

(11-430) Evaluation of Intravenous Amiodarone Use in Post-Cardiac Surgery Patients at Stony Brook University Hospital

(11-440) Evaluating the Effectiveness of an apixaban Order Set on the Selection of an Appropriate Dosing Regimen for Inpatients

(11-445) Assessment of heparin drip errors following implementation of a pharmacist driven aPTT protocol

(11-459) Title: Direct oral anticoagulants treatment failure for venous thromboembolism in the setting of thrombophilic conditions

(12-001) Evaluation of Intravenous Sotalol

(12-026) Effect of Dual Antiplatelet Therapy versus Single Antiplatelet Therapy on Bleeding Outcomes Following Transcatheter Aortic Valve Replacement

(12-029) Evaluation of the Adherence and Tolerability of Treprostinil DPI in Patients with WHO Groups 1 and 3 Pulmonary Hypertension

(12-031) Evaluation of the Utilization and Dosing of Intraoperative Digoxin at ECU Health Medical Center

(12-044) Assessment of Inpatient Sotalol Initiation Dosing for Atrial Fibrillation and Atrial Flutter

(12-045) Assessment of drug-drug interactions in hospitalized patients receiving direct oral anticoagulants

(12-060) Timing of Inpatient Renin-Angiotensin-Aldosterone System Inhibitor Administration Prior to Cardiac Surgery

(12-070) Evaluation and Management of Iron Deficiency in Patients Hospitalized for Heart Failure

(12-081) Assessing Appropriate Use of Low Dose Rivaroxaban as an Alternative to Prophylactic Enoxaparin

(12-088) Comparative Efficacy of Evolocumab and Alirocumab in Patients with Hyperlipidemia

(12-114) Evaluation of Sodium-Glucose Cotransporter 2 Inhibitors in Preventing Hospital Readmission due to Acute Heart Failure Exacerbations

(12-116) Retrospective Study of the Safety and Efficacy of Enoxaparin in Laparoscopic Sleeve Gastrectomy

(12-143) Fixed-dose versus Weight-based 4-Factor Prothrombin Complex Concentrate for Direct Oral Anticoagulant Reversal: Impact on Clinical Outcomes in Intracranial Hemorrhage.

(12-163) Dofetilide (Tikosyn) New Starts at a Large Academic Medical Center

(12-176) Evaluating the Efficacy of the Newly Implemented Anticoagulation Order Set Utilizing Enoxaparin vs. Heparin for Indications Such As A-Fib/Flutter, ACS (NSTEMI/ Troponin Elevation) and DVT/PE

(12-177) Development of a Pharmacy-Led Anti-Factor Xa Monitoring Protocol for High-Risk Populations on Enoxaparin